ВОЗ Международные Названия Субстанций

WHO Drug Information, Vol. 25, No.
4, 2011
Proposed INN: List 106
International Nonproprietary Names for

Pharmaceutical Substances (INN)
Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International
Nonproprietary Names for Pharmaceutical Substances, the names given in the list on the following pages are under
consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name
in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance
in medicine or pharmacy.
Lists of Proposed (1105) and Recommended (166) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only). The statements indicating action and use are based largely on information
supplied by the manufacturer. This information is merely meant to provide an indication of the potential use of new
substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to
uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these
descriptors will neither be revised nor included in the Cumulative Lists of INNs.
Dnominations communes internationales des

Substances pharmaceutiques (DCI)
Il est notifi que, conformment aux dispositions de l'article 3 de la Procdure suivre en vue du choix de Dnominations
communes internationales recommandes pour les Substances pharmaceutiques les dnominations ci-dessous sont mises
l'tude par l'Organisation mondiale de la Sant en tant que dnominations communes internationales proposes.
L'inclusion d'une dnomination dans les listes de DCI proposes n'implique aucune recommandation en vue de l'utilisation
de la substance correspondante en mdecine ou en pharmacie.
On trouvera d'autres listes de Dnominations communes internationales proposes (1105) et recommandes (166) dans
la Liste rcapitulative No. 14, 2011 (disponible sur CD-ROM seulement). Les mentions indiquant les proprits et les
indications des substances sont fondes sur les renseignements communiqus par le fabricant. Elles ne visent qu' donner
une ide de l'utilisation potentielle des nouvelles substances au moment o elles sont l'objet de propositions de DCI. L'OMS
n'est pas en mesure de confirmer ces dclarations ni de faire de commentaires sur l'efficacit du mode d'action ainsi dcrit.
En raison de leur caractre provisoire, ces informations ne figureront pas dans les listes rcapitulatives de DCI.
Denominaciones Comunes Internacionales para

las Sustancias Farmacuticas (DCI)
De conformidad con lo que dispone el prrafo 3 del "Procedimiento de Seleccin de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacuticas", se comunica por el presente anuncio que las
denominaciones detalladas en las pginas siguientes estn sometidas a estudio por la Organizacin Mundial de La Salud
como Denominaciones Comunes Internacionales Propuestas. La inclusin de una denominacin en las listas de las DCI
Propuestas no supone recomendacin alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1105) y Recomendadas (166) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible slo en CD-ROM). Las indicaciones sobre accin y uso que aparecen
se basan principalmente en la informacin facilitada por los fabricantes. Esta informacin tiene por objeto dar una idea
nicamente de las posibilidades de aplicacin de las nuevas sustancias a las que se asigna una DCI Propuesta. La OMS
no est facultada para respaldar esas indicaciones ni para formular comentarios sobre la eficacia de la accin que se
atribuye al producto. Debido a su carcter provisional, esos datos descriptivos no deben incluirse en las listas
recapitulativas de DCI.
413
WHO Drug Information, Vol. 25, No. 4, 2011
Proposed International Nonproprietary Names: List 106

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the
World Health Organization within four months of the date of their publication in WHO Drug Information, i.e., for List 106
Proposed INN not later than 31 May 2012
Publication Date: 31 January 2012
Dnominations communes internationales proposes: Liste 106

Des observations ou des objections formelles l'gard des dnominations proposes peuvent tre adresses par toute
personne au Programme des Dnominations communes internationales de l'Organisation mondiale de la Sant dans un
dlai de quatre mois compter de la date de leur publication dans WHO Drug Information, c'est dire pour la Liste 106 de
DCI Proposes le 31 mai 2012 au plus tard.
Date de publication: 31 janvier 2012
Denominaciones Comunes Internacionales Propuestas: Lista 106

Cualquier persona puede dirigir observaciones u objeciones respecto de las denominaciones propuestas, al Programa de
Denominaciones Comunes Internacionales de la Organizacin Mundial de la Salud, en un plazo de cuatro meses, contados
desde la fecha de su publicacin en WHO Drug Information, es decir, para la Lista 106 de DCI Propuestas el 31 de mayo
de 2012 a ms tardar.
Fecha de publicacin: 31 de enero de 2012
Proposed INN
(Latin, English, French, Spanish)
Chemical name or description: Action and use: Molecular formula

Chemical Abstracts Service (CAS) registry number: Graphic formula
DCI Propose
Nom chimique ou description: Proprits et indications: Formule brute

Numro dans le registre du CAS: Formule dveloppe
DCI Propuesta
Nombre qumico o descripcin: Accin y uso: Frmula molecular

Nmero de registro del CAS: Frmula desarrollada
acidum deoxycholicum
deoxycholic acid
3,12-dihydroxy-5-cholan-24-oic acid
endogenous bile salt
acide dsoxycholique
acide 3,12-dihydroxy-5-cholan-24-oque
sel biliaire endogne
cido desoxiclico
cido 3,12-dihidroxi-5-colan-24-oico
sal biliar endgena
83-44-3
C24H40O4
H 3C
OH
CH3
H
CH3
H
H
HO
414
H
H
H
H
CO2H
18
acidum florilglutamicum ( F)
18
florilglutamic acid ( F)
18
acide florilglutamique ( F)
18
cido florilglutamic ( F)
18
(4S)-4-(3-[ F]fluoropropyl)-L-glutamic acid

diagnostic aid
18
acide (4S)-4-(3-[ F]fluoropropyl)-L-glutamique

produit usage diagnostique
18
cido (4S)-4-(3-[ F]fluoropropil)-L-glutmico

agente de diagnstico
18
1196963-74-2
C8H14 FNO4
HO2C
CO2H
H H
NH2
[18F]
acidum tiazoticum
tiazotic acid
[(5-methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid
antioxidant
acide tiazotique
acide [(5-mthyl-1H-1,2,4-triazol-3-yl)sulfanyl]actique
antioxydant
cido tiaztico
cido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]actico
antioxidante
C5H7N3O2S
HN
H3 C
amitifadinum
amitifadine
64679-65-8
N
N
CO2H
(1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
antidepressant
amitifadine
(1R,5S)-1-(3,4-dichlorophnyl)-3-azabicyclo[3.1.0]hexane
antidpresseur
amitifadina
(1R,5S)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano
antidepresivo
C11H11Cl2N
410074-73-6
H
N
H
Cl
Cl
415
bamosiranum
bamosiran
siRNA inhibitor of 2-adrenergic receptor production;

RNA duplex of cytidylyl-(3'5')-adenylyl-(3'5')-uridylyl-(3'5')uridylyl-(3'5')-guanylyl-(3'5')-uridylyl-(3'5')-guanylyl-(3'5')cytidylyl-(3'5')-adenylyl-(3'5')-uridylyl-(3'5')-guanylyl-(3'5')uridylyl-(3'5')-guanylyl-(3'5')-adenylyl-(3'5')-uridylyl-(3'5')cytidylyl-(3'5')-cytidylyl-(3'5')-adenylyl-(3'5')-guanylyl-(3'5')thymidylyl-(3'5')-thymidine with thymidylyl-(5'3')-thymidylyl(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-adenylyl-(5'3')-adenylyl(5'3')-cytidylyl-(5'3')-adenylyl-(5'3')-cytidylyl-(5'3')-guanylyl(5'3')-uridylyl-(5'3')-adenylyl-(5'3')-cytidylyl-(5'3')-adenylyl(5'3')-cytidylyl-(5'3')-uridylyl-(5'3')-adenylyl-(5'3')-guanylyl(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidine
antiglaucoma
bamosiran
petit ARN interfrant (siRNA) inhibiteur de la production du rcepteur

adrnergique 2;
duplex ARN du brin cytidylyl-(3'5')-adnylyl-(3'5')-uridylyl-(3'
5')-uridylyl-(3'5')-guanylyl-(3'5')-uridylyl-(3'5')-guanylyl-(3'5')cytidylyl-(3'5')-adnylyl-(3'5')-uridylyl-(3'5')-guanylyl-(3'5')uridylyl-(3'5')-guanylyl-(3'5')-adnylyl-(3'5')-uridylyl-(3'5')cytidylyl-(3'5')-cytidylyl-(3'5')-adnylyl-(3'5')-guanylyl-(3'5')thymidylyl-(3'5')-thymidine avec le brin anti-sens thymidylyl-(5'
3')-thymidylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-adnylyl-(5'
3')-adnylyl-(5'3')-cytidylyl-(5'3')-adnylyl-(5'3')-cytidylyl-(5'
3')-guanylyl-(5'3')-uridylyl-(5'3')-adnylyl-(5'3')-cytidylyl-(5'
3')-adnylyl-(5'3')-cytidylyl-(5'3')-uridylyl-(5'3')-adnylyl-(5'
3')-guanylyl-(5'3')-guanylyl-(5'3')-uridylyl-(5'3')-cytidine
antiglaucomateux
bamosirn
ARN interferente pequeo (siRNA) inhibidor de la produccin del

receptor adrenrgico 2;
ARN dplex de la cadena citidilil-(3'5')-adenilil-(3'5')-uridilil-(3'
5')-uridilil-(3'5')-guanilil-(3'5')-uridilil-(3'5')-guanilil-(3'5')citidilil-(3'5')-adenilil-(3'5')-uridilil-(3'5')-guanilil-(3'5')-uridilil(3'5')-guanilil-(3'5')-adenilil-(3'5')-uridilil-(3'5')-citidilil-(3'5')citidilil-(3'5')-adenilil-(3'5')-guanilil-(3'5')-timidilil-(3'5')timidina con la cadena antisentido timidilil-(5'3')-timidilil-(5'3')guanilil-(5'3')-uridilil-(5'3')-adenilil-(5'3')-adenilil-(5'3')-citidilil(5'3')-adenilil-(5'3')-citidilil-(5'3')-guanilil-(5'3')-uridilil-(5'3')adenilil-(5'3')-citidilil-(5'3')-adenilil-(5'3')-citidilil-(5'3')-uridilil(5'3')-adenilil-(5'3')-guanilil-(5'3')-guanilil-(5'3')-uridilil-(5'
3')-citidina
antiglaucoma
C401H500N150O290P40
1337968-84-9
(3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT
(5'-3')dT-dT-GUAACACGUACACUAGGUC
416
brexpiprazolum
brexpiprazole
7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin2(1H)-one
antipsychotic
brexpiprazole
7-{4-[4-(1-benzothiophn-4-yl)piprazin-1-yl]butoxy}quinolin2(1H)-one
antipsychotique
brexpiprazol
7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1H)-ona
antisictico
C22H27N3O2S
913611-97-9
O
N
S
buparlisibum
buparlisib
H
N
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin2-amine
antineoplastic
buparlisib
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromthyl)pyridin2-amine
antinoplasique
buparlisib
5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina
antineoplsico
944396-07-0
C18H21F3N6O2
O
N
N
N
O
camicinalum
camicinal
N
F3C
NH2
1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-(4-{[(3S)-3methylpiperazin-1-yl]methyl}phenyl)ethan-1-one
digestive agent
camicinal
1-{4-[(3-fluorophnyl)amino]pipridin-1-yl}-2-(4-{[(3S)-3mthylpiprazin-1-yl]mthyl}phnyl)than-1-one
rgulateur des fonctions digestives
camicinal
1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-(4-{[(3S)-3-metilpiperazin1-il]metil}fenil)etan-1-ona
digestivo
417
C25H33FN4O
923565-21-3
HN
H
caplacizumabum #
caplacizumab
F
N
CH3
N
H
immunoglobulin VH-linker-VH fragment, anti-[Homo sapiens VWF

(von Willebrand factor) A1 domain], humanized monoclonal
antibody;
VH-linker-VH chain (1-259) [humanized VH (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)) trialanyl linker (129-131) -[humanized VH (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)
anti-von Willebrand factor
caplacizumab
immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF

(facteur de von Willebrand) domaine A1], anticorps monoclonal
humanis;
chane VH-linker-VH (1-259) [VH humanis (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)) trialanyl linker (129-131) -[VH humanis (Homo sapiens IGHV323*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)
anti-facteur de Von Willebrand
caplacizumab
inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de

von Willebrand) de Homo sapiens dominio A1], anticuerpo
monoclonal humanizado
cadena VH-conector-VH (1-259) [VH humanizado (Homo sapiens
IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21]
(1-128)] -trialanil conector (129-131) -[VH humanizado (Homo
sapiens IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254)
[8.8.21] (132-259)
inhibidor del factor Von Willebrand
915810-67-2
EVQLVESGGG
ISRTGGSTYY
VRAEDGRVRT
LSCAASGRTF
ISRDNAKRMV
QGTQVTVSS
LVQPGGSLRL
PDSVEGRFTI
LPSEYTFWGQ
SYNPMGWFRQ
YLQMNSLRAE
SCAASGRTFS
SRDNAKRMVY
GTQVTVSSAA
APGKGRELVA
DTAVYYCAAA
YNPMGWFRQA
LQMNSLRAED
AEVQLVESGG
AISRTGGSTY
GVRAEDGRVR
PGKGRELVAA
TAVYYCAAAG
GLVQPGGSLR
YPDSVEGRFT
TLPSEYTFWG
50
100
150
200
250
259
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 22-96 153-227
cerlapirdinum
cerlapirdine
cerlapirdine
418
N,N-dimethyl-3-{[3-(naphthalene-1-sulfonyl)-1H-indazol5-yl]oxy}propan-1-amine
serotonin receptor antagonist
N,N-dimthyl-3-{[3-(naphtalne-1-sulfonyl)-1H-indazol5-yl]oxy}propan-1-amine
antagoniste des rcepteurs de la srotonine
cerlapirdina
N,N-dimetil-3-{[3-(naftaleno-1-sulfonil)-1H-indazol-5-il]oxi}propan1-amina
antagonista del receptor de la serotonina
C22H23N3O3S
925448-93-7
H
N
H3C
N
N
CH3
dexmecamylaminum
dexmecamylamine
S
O
(1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
antidepressant
dexmcamylamine
(1R,2S,4S)-N,2,3,3-ttramthylbicyclo[2.2.1]heptan-2-amine
antidpresseur
dexmecamilamina
(1R,2S,4S)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina
antidepresivo
C11H21N
H
drisapersenum
drisapersen
drisapersen
HN
107538-05-6
CH3
CH3
CH3
CH3
all-P-ambo-2'-O-methyl-P-thiouridylyl-(3'5')-2'-O-methyl-Pthiocytidylyl-(3'5')-2'-O-methyl-P-thioadenylyl-(3'5')-2'-O-methylP-thioadenylyl-(3'5')-2'-O-methyl-P-thioguanylyl-(3'5')-2'-Omethyl-P-thioguanylyl-(3'5')-2'-O-methyl-P-thioadenylyl-(3'5')-2'O-methyl-P-thioadenylyl-(3'5')-2'-O-methyl-P-thioguanylyl-(3'5')2'-O-methyl-P-thioadenylyl-(3'5')-2'-O-methyl-P-thiouridylyl(3'5')-2'-O-methyl-P-thioguanylyl-(3'5')-2'-O-methyl-Pthioguanylyl-(3'5')-2'-O-methyl-P-thiocytidylyl-(3'5')-2'-O-methylP-thioadenylyl-(3'5')-2'-O-methyl-P-thiouridylyl-(3'5')-2'-Omethyl-P-thiouridylyl-(3'5')-2'-O-methyl-P-thiouridylyl-(3'5')-2'-Omethyl-P-thiocytidylyl-(3'5')-2'-O-methyluridine
treatment of Duchenne muscular dystrophy
tout-P-ambo-2'-O-mthyl-P-thiouridylyl-(3'5')-2'-O-mthyl-Pthiocytidylyl-(3'5')-2'-O-mthyl-P-thioadnylyl-(3'5')-2'-O-mthylP-thioadnylyl-(3'5')-2'-O-mthyl-P-thioguanylyl-(3'5')-2'-Omthyl-P-thioguanylyl-(3'5')-2'-O-mthyl-P-thioadnylyl-(3'5')-2'O-mthyl-P-thioadnylyl-(3'5')-2'-O-mthyl-P-thioguanylyl-(3'5')2'-O-mthyl-P-thioadnylyl-(3'5')-2'-O-mthyl-P-thiouridylyl(3'5')-2'-O-mthyl-P-thioguanylyl-(3'5')-2'-O-mthyl-Pthioguanylyl-(3'5')-2'-O-mthyl-P-thiocytidylyl-(3'5')-2'-O-mthylP-thioadnylyl-(3'5')-2'-O-mthyl-P-thiouridylyl-(3'5')-2'-Omthyl-P-thiouridylyl-(3'5')-2'-O-mthyl-P-thiouridylyl-(3'5')-2'-Omthyl-P-thiocytidylyl-(3'5')-2'-O-mthyluridine
traitement de la myopathie de Duchenne
419
drisapersn
todo-P-ambo-2'-O-metil-P-tiouridilil-(3'5')-2'-O-metil-P-tiocitidilil(3'5')-2'-O-metil-P-tioadenilil-(3'5')-2'-O-metil-P-tioadenilil(3'5')-2'-O-metil-P-tioguanilil-(3'5')-2'-O-metil-P-tioguanilil(3'5')-2'-O-metil-P-tioadenilil-(3'5')-2'-O-metil-P-tioadenilil(3'5')-2'-O-metil-P-tioguanilil-(3'5')-2'-O-metil-P-tioadenilil(3'5')-2'-O-metil-P-tiouridilil-(3'5')-2'-O-metil-P-tioguanilil-(3'5')2'-O-metil-P-tioguanilil-(3'5')-2'-O-metil-P-tiocitidilil-(3'5')-2'-Ometil-P-tioadenilil-(3'5')-2'-O-metil-P-tiouridilil-(3'5')-2'-O-metil-Ptiouridilil-(3'5')-2'-O-metil-P-tiouridilil-(3'5')-2'-O-metil-P-tiocitidilil(3'5')-2'-O-metiluridina
tratamiento de la distrofia muscular de Duchenne
1251830-50-8
C211H275N76O119P19S19
(3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)
faldaprevirum
faldaprevir
(1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-2-[2-(2methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]-1-[(2S)-2{[(cyclopentyloxy)carbonyl]amino}-3,3-dimethylbutanoyl]pyrrolidine2-carboxamido]-2-ethenylcyclopropane-1-carboxylic acid
antiviral
faldaprvir
acide (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-mthoxy-2-[2-(2mthylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]-1-[(2S)-2{[(cyclopentyloxy)carbonyl]amino}-3,3-dimthylbutanoyl]pyrrolidine2-carboxamido]-2-thnylcyclopropane-1-carboxylique
antiviral
faldaprevir
cido (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-2-[2-(2metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il}oxi]-1-[(2S)-2{[(ciclopentiloxi)carbonil]amino}-3,3-dimetilbutanoil]pirrolidina2-carboxamido}-2-etenilciclopropano-1-carboxlico
antiviral
C40H49BrN6O9S
801283-95-4
S
Br
H3CO
H3C
O
O
CH3
CH3
H
N
H
H
N
CH3
CO2H
CH2
O
H
420
CH3
N
H
NH
N
flanvotumabum #
flanvotumab
immunoglobulin G1-kappa, anti-[Homo sapiens TYRP1 (tyrosinaserelated protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase,
DHICA oxidase, TRP1, melanoma antigen gp75)], Homo sapiens
monoclonal antibody;
gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer
antineoplastic
flanvotumab
immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protine 1

apparente la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole2-carboxylique, DHICA-oxydase, TRP1, antigne gp75 du
mlanome)], Homo sapiens anticorps monoclonal;
chane lourde gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfure avec la chane lgre kappa (1'-215') [Homo
sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'108') -IGKC*01 (109'-215')]; dimre (228-228'':231-231'')-bisdisulfure
antinoplasique
flanvotumab
inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina

1 relacionada con la tirosinasa), oxidasa del cido 5,6-dihidroxiindol2-carboxlico, DHICA-oxidasa, TRP1, antgeno gp75 de melanoma]],
anticuerpo monoclonal de Homo sapiens;
cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'108') -IGKC*01 (109'-215')]; dmero (228-228'':231-231'')-bisdisulfuro
antineoplsico
1188277-05-5
Heavy chain / Chane lourde / Cadena pesada
QVQLVQSGSE LKKPGASVKI SCKASGYTFT
INTNTGNPTY AQGFTGRFVF SMDTSVSTAY
SSSWYLDYWG QGTLVTVSSA STKGPSVFPL
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
Light chain / Chane lgre / Cadena ligera
EIVLTQSPAT LSLSPGERAT LSCRASQSVS
ASNRATGIPA RFSGSGSGTD FTLTISSLEP
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT
VDNALQSGNS QESVTEQDSK DSTYSLSSTL
GLSSPVTKSF NRGEC
SYAMNWVRQA
LQISSLKAED
APSSKSTSGG
LYSLSSVVTV
CPAPELLGGP
VDGVEVHNAK
PAPIEKTISK
VEWESNGQPE
HEALHNHYTQ
PGQGLESMGW
TAIYYCAPRY
TAALGCLVKD
PSSSLGTQTY
SVFLFPPKPK
TKPREEQYNS
AKGQPREPQV
NNYKTTPPVL
KSLSLSPGK
50
100
150
200
250
300
350
400
449
SYLAWYQQKP
EDFAVYYCQQ
ASVVCLLNNF
TLSKADYEKH
GQAPRLLIYD 50
RSNWLMYTFG 100
YPREAKVQWK 150
KVYACEVTHQ 200
215
Intra-H 22-96 146-202 263-323
369-427
22''-96'' 146''-202'' 263''-323'' 369''-427''
Intra-L 23'-88' 135'-195'
23'''-88''' 135'''-195'''
Inter-H-L 222-215' 222''-215'''
Inter-H-H 228-228'' 231-231''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilacin
299, 299''
421
follitropinum gamma #
follitropin gamma
heterodimer of human glycoprotein hormones alpha chain and

follitropin subunit beta (FSH-beta), follicle stimulating hormone,
glycoform gamma
follicle stimulating hormone
follitropine gamma
htrodimre constitu de la chane alpha des hormones

glycoprotiques et de la sous-unit bta de la follitropine (FSH-bta)
humaines, hormone folliculostimulante, forme glycosyle gamma
hormone folliculostimulante
folitropina gamma
heterodmero formado por la cadena alfa de las hormonas

glicoproticas y la subunidad beta de la folitropina (FSH-beta)
humanas, hormona estimulante del folculo, forma glicosilada
gamma
hormona estimulante del folculo
C975H1493N267O305S26 (peptide)
1219693-73-8
Alpha subunit / Sous-unit alpha / Subunidad alfa

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS
50
92
Beta subunit / Sous-unit bta / Subunidad beta

NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
PSYCSFGEMK E
111'
7-31 10-60 28-82
32-84 59-87
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilacin (N)
Asn-7' Asn-24' Asn-52 Asn-78
R66R33--Gal4--Gl-N2R44R33--Gal4--Gl-N2-
R6
-Man6-
-Man4--Gl-N4
-Gl-NN
-Man3-
R = -Fuc or H, R3 = -Sia or H, R4 and R6 = R33--Gal4--Gl-N or H
gemcitabini elaidas
gemcitabine elaidate
2'-deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate
antineoplastic
ladate de gemcitabine
5'-(9E)-octadc-9-noate de 2'-doxy-2',2'-difluorocytidine
antinoplasique
elaidato de gemcitabina
5'-(9E)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina
antineoplsico
210829-30-4
C27H43F2N3O5
NH2
N
O
O
O
CH3
422
F
OH
glyceroli phenylbutyras
glycerol phenylbutyrate
propane-1,2,3-triyl tris(4-phenylbutanoate)
urea cycle disorders
phnylbutyrate de glycrol
tris(4-phnylbutanoate) de propane-1,2,3-triyle
dsordres du cycle de l'ure
fenilbutirato de glicerol
tris(4-fenilbutanoato) de propano-1,2,3-triilo
alteraciones del ciclo de la urea
611168-24-2
C33H38O6
O
O
O
O
idursulfasum beta #
idursulfase beta
iduronate 2-sulfatase (-L-iduronate sulfate sulfatase), human proenzyme produced in CHO cells (glycoform beta)
enzyme
idursulfase bta
iduronate 2-sulfatase (-L-iduronate sulfate sulfatase), proenzyme

humaine produite par des cellules CHO (glycoforme bta)
enzyme
idursulfasa beta
iduronato 2-sulfatasa (-L-iduronato sulfato sulfatasa), proenzima

humana producida por clulas CHO (forma glicosilada beta)
enzima
C2689H4051N699O793S13
SETQANSTTD
NAFAQQAVCA
NGYVTMSVGK
GELHANLLCP
HKPHIPFRYP
VQALNISVPY
STIIAFTSDH
KLFPYLDPFD
SFHVELCREG
NSDKPSLKDI
DSDPLQDHNM
1271734-34-9
ALNVLLIIVD
PSRVSFLTGR
VFHPGISSNH
VDVLDVPEGT
KEFQKLYPLE
GPIPVDFQRK
GWALGEHGEW
SASQLMEPGR
KNLLKHFRFR
KIMGYSIRTI
YNDSQGGDLF
DLRPSLGCYG
RPDTTRLYDF
TDDSPYSWSF
LPDKQSTEQA
NITLAPDPEV
IRQSYFASVS
AKYSNFDVAT
QSMDLVELVS
DLEEDPYLPG
DYRYTVWVGF
QLLMP
DKLVRSPNID
NSYWRVHAGN
PPYHPSSEKY
IQLLEKMKTS
PDGLPPVAYN
YLDTQVGRLL
HVPLIFYVPG
LFPTLAGLAG
NPRELIAYSQ
NPDEFLANFS
QLASHSLLFQ
FSTIPQYFKE
ENTKTCRGPD
ASPFFLAVGY
PWMDIRQRED
SALDDLQLAN
RTASLPEAGE
LQVPPRCPVP
YPRPSDIPQW
DIHAGELYFV
50
100
150
200
250
300
350
400
450
500
525
146-159 397-407
Modified residue / Rsidu modifi / Residuo modificado
C
59
3-oxoAla
H
O
NH2
CO2H
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilacin (N)

Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512
423
inclacumabum #
inclacumab
immunoglobulin G4-kappa, anti-[Homo sapiens SELP (selectin P,

CD62)], Homo sapiens monoclonal antibody;
gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with
kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01
(100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230230'':233-233'')-bisdisulfide dimer
antithrombotic
inclacumab
immunoglobuline G4-kappa, anti-[Homo sapiens SELP (slectine P,

CD62)], Homo sapiens anticorps monoclonal;
chane lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnire
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure
avec la chane lgre kappa (1'-214') [Homo sapiens V-KAPPA
(IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01
(108'-214')]; dimre (230-230'':233-233'')-bisdisulfure
antithrombotique
inclacumab
inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina

P, CD62)], anticuerpo monoclonal de Homo sapiens ;
cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con
la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV311*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
dmero (230-230'':233-233'')-bisdisulfuro
antitrombtico
1256258-86-2
EVQLVESGGG LVRPGGSLRL SCAASGFTFS
ITAAGDIYYP GSVKGRFTIS RENAKNSLYL
SGSGSYYNDW FDPWGQGTLV TVSSASTKGP
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
GTKTYTCNVD HKPSNTKVDK RVESKYGPPC
PKDTLMISRT PEVTCVVVDV SQEDPEVQFN
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK
QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD
VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS
K
NYDMHWVRQA
QMNSLRAGDT
SVFPLAPCSR
LQSSGLYSLS
PPCPAPEFEG
WYVDGVEVHN
GLPSSIEKTI
IAVEWESNGQ
VMHEALHNHY
TGKGLEWVSA
AVYYCARGRY
STSESTAALG
SVVTVPSSSL
GPSVFLFPPK
AKTKPREEQF
SKAKGQPREP
PENNYKTTPP
TQKSLSLSLG

EIVLTQSPAT LSLSPGERAT LSCRASQSVS
ASNRATGIPA RFSGSGSGTD FTLTISSLEP
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSSPVTKSFN RGEC
SYLAWYQQKP
EDFAVYYCQQ
SVVCLLNNFY
LSKADYEKHK
GQAPRLLIYD 50
RSNWPLTFGG 100
PREAKVQWKV 150
VYACEVTHQG 200
214
50
100
150
200
250
300
350
400
450
451
Intra-H 22-95 151-207
265-325
371-429
22''-95'' 151''-207'' 265''-325'' 371''-429''
Intra-L 23'-88'
134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 138-214' 138''-214'''
Inter-H-H 230-230'' 233-233''
301, 301''
424
lucerastatum
lucerastat
(2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
ceramide glucosyltransferase inhibitor
lucrastat
(2R,3S,4R,5S)-1-butyl-2-(hydroxymthyl)pipridine-3,4,5-triol
inhibiteur de la glycosylcramide transfrase
lucerastat
(2R,3S,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol
inhibidor de la glicosilceramida transferasa
141206-42-0
C10H21NO4
OH
HO
H
HO
H
N
CH3
H
OH
naltalimidum
naltalimide
2-[17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan6-yl]isoindole-1,3-dione
-opioid receptor partial agonist
naltalimide
2-[-17-(cyclopropylmthyl)-4,5-poxy-3,14-dihydroxymorphinan6-yl]-2H-isoindole-1,3-dione
agoniste partiel des rcepteurs opiodes
naltalimida
2-[17-(ciclopropilmetil)-4,5-epoxi-3,14-dihidroximorfinan6-il]isoindol-1,3-diona
agonista parcial de los receptores de opiceos
160359-68-2
C28H28N2O5
H
HO
O
HO
H H
niraparibum
niraparib
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
antineoplastic
niraparib
2-{4-[(3S)-pipridin-3-yl]phnyl}-2H-indazole-7-carboxamide
antinoplasique
niraparib
2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
antineoplsico
425
C19H20N4O
1038915-60-4
H
N
N
N
ondelopranum
ondelopran
NH2
6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine3-carboxamide
opioid receptor antagonist
ondlopran
6-[2-fluoro-4-({[2-(oxan-4-yl)thyl]amino}mthyl)phnoxy]pyridine3-carboxamide
antagoniste des rcepteurs opiodes
ondeloprn
6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina3-carboxamida
antagonista de los receptores de opiceos
676501-25-0
C20H24FN3O3
O
O
N
H
NH2
O
F
patiromerum calcium
patiromer calcium
cross-linked polymer of calcium 2-fluoroprop-2-enoate with

diethenylbenzene and octa-1,7-diene
potassium binder
patiromre calcique
polymre rticul de 2-fluoroprop-2-noate de calcium avec du

dithnylbenzne et de l'octa-1,7-dine
ligand du potassium
patirmero clcico
polmero reticulado de 2-fluoroprop-2-enoato de calcio con

dietenilbenceno y octa-1,7-dieno
quelante de potasio
[[(C3H2FO2)2 Ca]9 [C8H14] [C10H10]]n
H2C
CO2
F
x/2 Ca2+
426
1208912-84-8
CH2
H2C
H2C
CH2
z
patritumabum #
patritumab
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor

tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal
antibody;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
immunomodulator, antineoplastic
patritumab
immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (rcepteur

tyrosine-protine kinase erbB3, HER3)], Homo sapiens anticorps
monoclonal;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
immunomodulateur, antinoplasique
patritumab
inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor de

tirosina-proteina kinasa erbB3, HER3)], anticuerpo monoclonal de
Homo sapiens;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
inmunomodulador, antineoplsico
1262787-83-6
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS
INHSGSTNYN PSLKSRVTIS VETSKNQFSL
TWYFDLWGRG TLVTVSSAST KGPSVFPLAP
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP
LMISRTPEVT CVVVDVSHED PEVKFNWYVD
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
DIEMTQSPDS LAVSLGERAT INCRSSQSVL
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
EVTHQGLSSP VTKSFNRGEC
GYYWSWIRQP
KLSSVTAADT
SSKSTSGGTA
SLSSVVTVPS
APELLGGPSV
GVEVHNAKTK
PIEKTISKAK
WESNGQPENN
ALHNHYTQKS
PGKGLEWIGE
AVYYCARDKW
ALGCLVKDYF
SSLGTQTYIC
FLFPPKPKDT
PREEQYNSTY
GQPREPQVYT
YKTTPPVLDS
LSLSPGK
50
100
150
200
250
300
350
400
447
YSSSNRNYLA
ISSLQAEDVA
LKSGTASVVC
LSSTLTLSKA
WYQQNPGQPP 50
VYYCQQYYST 100
LLNNFYPREA 150
DYEKHKVYAC 200
220
Intra-H 22-95
144-200
261-321
367-425
22''-95'' 144''-200'' 261''-321'' 367''-425''
Intra-L 23'-94'
140'-200'
23'''-94''' 140'''-200'''
Inter-H-L 220-220' 220''-220'''
Inter-H-H 226-226'' 229-229''
297, 297''
427
plazomicinum
plazomicin
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl]oxy}2-{[3-deoxy-4-C-methyl-3-(methylamino)--L-arabinopyranosyl]oxy}3-hydroxycyclohexyl]-2-hydroxybutanamide
antibiotic
plazomicine
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hydroxythyl)amino]mthyl}-3,4-dihydro-2H-pyran-2-yl]oxy}2-{[3-doxy-4-C-mthyl-3-(mthylamino)--L-arabinopyranosyl]oxy}3-hydroxycyclohexyl]-2-hydroxybutanamide
antibiotique
plazomicina
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino6-{[(2-hidroxietil)amino]metil}-3,4-dihidro-2H-piran-2-il]oxi}2-{[3-desoxi-4-C-metil-3-(metilamino)--L-arabinopiranosil]oxi}3-hidroxiciclohexil]-2-hidroxibutanamida
antibitico
1154757-24-0
C25H48N6O10
HO
HO
HN
HN
O
CH3
H3 C
NH2
HN
H OH
OH
O HO
NH2
pradigastatum
pradigastat
NH2
{(1r,4r)-4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)
phenyl]cyclohexyl}acetic acid
antihyperlipidaemic
pradigastat
acide {trans-4-[4-(5-{[6-(trifluoromthyl)pyridin-3-yl]amino}pyridin2-yl)phnyl]cyclohexyl}actique
antihyperlipidmiant
pradigastat
cido {(1r,4r)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il)
fenil]ciclohexil}actico
antihiperlipmico
C25H24F3N3O2
956136-95-1
CO2H
F3C
N
N
H
428
pritelivirum
pritelivir
N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin2-yl)phenyl]acetamide
antiviral
pritlivir
N-mthyl-N-(4-mthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin2-yl)phnyl]actamide
antiviral
pritelivir
N-metil-N-(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin2-il)fenil]acetamida
antiviral
348086-71-5
C18H18N4O3S2
N
CH3
O
NH2
N
N
S
O
CH3
quilizumabum #
quilizumab
immunoglobulin G1-kappa, anti-[Homo sapiens IGHE connecting

region (CO) M1 prime (in alternatively spliced heavy chain of
membrane IgE on B cells)], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
(Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112')
-Homo sapiens IGKC*01 (113'-219')]; (226-226":229-229")bisdisulfide dimer
immunomodulator
quilizumab
immunoglobuline G1-kappa, anti-[Homo sapiens IGHE rgion de

connexion (CO) M1 prime (dans la chane lourde des IgE
membranaires la surface des lymphocytes B, pisse de manire
alternative)], anticorps monoclonal humanis;
chane lourde gamma1 (1-447) [VH humanis (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfure avec la chane lgre kappa (1'-219') [V-KAPPA
humanis (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimre (226226":229-229")-bisdisulfure
immunomodulateur
quilizumab
inmunoglobulina G1-kappa, anti-[Homo sapiens IGHE regin de

conexin (CO) M1 prime (en la cadena pesada de las IgE de
membrana de la superficie de los linfocitos B, ensamblada de modo
alternativo)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dmero (226226":229-229")-bisdisulfuro
inmunomodulador
429
1228538-47-3
EVQLVESGGG LVQPGGSLRL SCAASGFTFS
ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY
WDAMDYWGQG TLVTVSSAST KGPSVFPLAP
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP
LMISRTPEVT CVVVDVSHED PEVKFNWYVD
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE
DIQMTQSPSS LSASVGDRVT ITCRSSQSLV
LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
VTHQGLSSPV TKSFNRGEC
DYGIAWVRQA
LQMNSLRAED
SSKSTSGGTA
SLSSVVTVPS
APELLGGPSV
GVEVHNAKTK
PIEKTISKAK
WESNGQPENN
ALHNHYTQKS
PGKGLEWVAF
TAVYYCARDN
ALGCLVKDYF
SSLGTQTYIC
FLFPPKPKDT
PREEQYNSTY
GQPREPQVYT
YKTTPPVLDS
LSLSPGK
50
100
150
200
250
300
350
400
447
HNNANTYLHW
SSLQPEDFAT
KSGTASVVCL
SSTLTLSKAD
YQQKPGKAPK 50
YYCSQNTLVP 100
LNNFYPREAK 150
YEKHKVYACE 200
219
Intra-H 22-96
144-200
261-321
367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L 23'-93'
139'-199'
23'''-93''' 139'''-199'''
Inter-H-L 220-219' 220''-219'''
Inter-H-H 226-226'' 229-229''
297, 297'' (non-fucosylated oligosaccharides)
radavirsenum
radavirsen
430
all-P-ambo-P,2',3'-trideoxy-P-(dimethylamino)-5'-O-{P-[4-(10hydroxy-2,5,8-trioxadecanoyl)piperazin-1-yl]-N,Ndimethylphosphonamidoyl}-(2'a5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a5')P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly(2'a5')-P,3'-dideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'secothymidylyl-(2'a5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino2',3'-secothymidylyl-(2'a5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'imino-2',3'-secoadenylyl-(2'a5')-P,2',3'-trideoxy-P-(dimethylamino)2',3'-imino-2',3'-secoguanyly-(2'a5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a5')P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly(2'a5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'secoadenylyl-(2'a5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino2',3'-secocytidylyl-(2'a5')-P,3'-dideoxy-P-(dimethylamino)-2',3'imino-2',3'-secothymidylyl-(2'a5')-P,2',3'-trideoxy-P(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a5')-P,2',3'trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a5')P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl(2'a5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'secocytidylyl-(2'a5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino2',3'-secothymidylyl-(2'a5')-P,3'-dideoxy-P-(dimethylamino)-2',3'imino-2',3'-secothymidylyl-(2'a5')-P,3'-dideoxy-P-(dimethylamino)2',3'-imino-2',3'-secothymidine
antiviral
radavirsen
tout-P-ambo-P,2',3'-tridoxy-P-(dimthylamino)-5'-O-{P-[4-(10hydroxy-2,5,8-trioxadcanoyl)piprazin-1-yl]-N,Ndimthylphosphonamidoyl}-2',3'-imino-2',3'-scocytidylyl-(2'a5')P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino-2',3'-scoguanylyl(2'a5')-P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino-2',3'scoguanylyl-(2'a5')-P,3'-didoxy-2',3'-imino-P-(piprazin-1-yl)2',3'-scothymidylyl-(2'a5')-P,3'-didoxy-P-(dimthylamino)-2',3'imino-2',3'-scothymidylyl-(2'a5')-P,2',3'-tridoxy-P(dimthylamino)-2',3'-imino-2',3'-scoadnylyl-(2'a5')-P,2',3'tridoxy-P-(dimthylamino)-2',3'-imino-2',3'-scoguanylyl-(2'a5')P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino-2',3'-scoadnylyl(2'a5')-P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino-2',3'scoadenylyl-(2'a5')-P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino2',3'-scoguanylyl-(2'a5')-P,2',3'-tridoxy-P-(dimthylamino)-2',3'imino-2',3'-scoadnylyl-(2'a5')-P,2',3'-tridoxy-2',3'-imino-P(piprazin-1-yl)-2',3'-scocytidylyl-(2'a5')-P,3'-didoxy-P(dimthylamino)-2',3'-imino-2',3'-scothymidylyl-(2'a5')-P,2',3'tridoxy-P-(dimthylamino)-2',3'-imino-2',3'-scocytidylyl-(2'a5')P,2',3'-tridoxy-P-(dimthylamino)-2',3'-imino-2',3'-scoadnylyl(2'a5')-P,3'-didoxy-P-(dimethylamino)-2',3'-imino-2',3'scothymidylyl-(2'a5')-P,2',3'-tridoxy-2',3'-imino-P-(piprazin1-yl)-2',3'-scocytidylyl-(2'a5')-P,3'-didoxy-P-(dimthylamino)2',3'-imino-2',3'-scothymidylyl-(2'a5')-P,3'-didoxy-P(dimthylamino)-2',3'-imino-2',3'-scothymidylyl-(2'a5')-3'-doxy2',3'-imino-2',3'-scothymidine
antiviral
radavirsn
todo-P-ambo-P,2',3'-tridesoxi-P-(dimetilamino)-5'-O-{P-[4-(10hidroxi-2,5,8-trioxadecanoil)piperazin-1-yl]-N,N-dimetilfosfonamidoil}(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'secocitidilil-(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino2',3'-secoguanilil-(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'imino-2',3'-secoguanilil-(2'a5')-P,3'-didesoxi-P-(piperazin-1-il)-2',3'imino-2',3'-secotimidilil-(2'a5')-P,3'-didesoxi-P-(dimetilamino)-2',3'imino-2',3'-secotimidilil-(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)2',3'-imino-2',3'-secoadenilil-(2'a5')-P,2',3'-tridesoxi-P(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a5')-P,2',3'-tridesoxiP-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a5')-P,2',3'tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a5')P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoguanilil(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'secoadenilil-(2'a5')-P,2',3'-tridesoxi-P-(piperazin-1-il)-2',3'-imino2',3'-secocitidilil-(2'a5')-P,3'-didesoxi-P-(dimetilamino)-2',3'-imino2',3'-secotimidilil-(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'imino-2',3'-secocitidilil-(2'a5')-P,2',3'-tridesoxi-P-(dimetilamino)2',3'-imino-2',3'-secoadenilil-(2'a5')-P,3'-didesoxi-P-(dimetilamino)2',3'-imino-2',3'-secotimidilil-(2'a5')-P,2',3'-tridesoxi-P-(piperazin-1il)-2',3'-imino-2',3'-secocitidilil-(2'a5')-P,3'-didesoxi-P(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a5')-P,3'-didesoxi-P(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a5')-P,3'-didesoxi-P(dimetilamino)-2',3'-imino-2',3'-secotimidina
antiviral
431
1228284-45-4
C253H398N116O87P20
O
B(n)
B(20)
O 1'
HO
N
3
H3C
N O
CH3
n = 1 - 19
2'a
O
5'
O
N
R(n) O
NH
19
B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T
R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH3)2
R(4) = R(12) = R(17) = HN
rafigrelidum
rafigrelide
6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-b]quinazolin2(3H)-one
platelet aggregation inhibitor
rafigrlide
6,7-dichloro-3,3-dimthyl-1,5-dihydroimidazo[2,1-b]quinazolin2(3H)-one
antiagrgant plaquettaire
rafigrelida
6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-b]quinazolin2(3H)-ona
inhibidor de la agregacion plaqueteria
C12H11Cl2N3O
1029711-88-3
H
N
N
N
Cl
Cl
refametinibum
refametinib
H 3C
O
CH3
N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
antineoplastic
rfamtinib
N-{3,4-difluoro-2-[(2-fluoro-4-iodophnyl)amino]-6-mthoxyphnyl}1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
antinoplasique
refametinib
N-{3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil}1-[(2S)-2,3-dihidroxipropil]ciclopropano-1-sulfonamida
antineoplsico
432
C19H20F3IN2O5S
923032-37-5
CH3
O
O O
N
H
NH
I
rigosertibum
rigosertib
OH
H OH
N-[2-methoxy-5-({[(1E)-2-(2,4,6trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
antineoplastic
rigosertib
N-[2-mthoxy-5-({[(1E)-2-(2,4,6trimthoxyphnyl)thnyl]sulfonyl}mthyl)phnyl]glycine
antinoplasique
rigosertib
N-[2-metoxi-5-({[(1E)-2-(2,4,6trimetoxifenil)etenil]sulfonil}metil)fenil]glicina
antineoplsico
C21H25NO8S
H3CO
592542-59-1
OCH3
S
OCH3
romosozumabum #
romosozumab
romosozumab
O O
H
N
CO2H
OCH3
immunoglobulin G2-kappa, anti-[Homo sapiens SOST (sclerostin)],

humanized monoclonal antibody;
gamma2 heavy chain (1-449) [humanized VH (Homo sapiens
IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T
(118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA
(Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; (225-225":226-226":229229":232-232")-tetrakisdisulfide dimer
immunomodulator
immunoglobuline G2-kappa, anti-[Homo sapiens SOST
(sclrostine)], anticorps monoclonal humanis;
chane lourde gamma2 (1-449) [VH humanis (Homo sapiens
(118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfure avec la chane lgre kappa (1'-214') [V-KAPPA
humanis (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9]
(1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimre (225225":226-226":229-229":232-232")-ttrakisdisulfure
immunomodulateur
433
romosozumab
inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de Homo

sapiens], anticuerpo monoclonal humanizado;
cadena pesada gamma2 (1-449) [VH humanizado (Homo sapiens
(118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
humanizado (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02)
[6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dmero (225225":226-226":229-229":232-232")-tetrakisdisulfuro
inmunomodulador
909395-70-6
EVQLVQSGAE VKKPGASVKV SCKASGYTFT
INPNSGGAGY NQKFKGRVTM TTDTSTSTAY
YDDIYDDWYF DVWGQGTTVT VSSASTKGPS
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL
TQTYTCNVDH KPSNTKVDKT VERKCCVECP
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM
DIQMTQSPSS LSASVGDRVT ITCRASQDIS
TSRLLSGVPS RFSGSGSGTD FTLTISSLQP
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA
LSSPVTKSFN RGEC
DYNMHWVRQA
MELRSLRSDD
VFPLAPCSRS
QSSGLYSLSS
PCPAPPVAGP
VDGVEVHNAK
PAPIEKTISK
VEWESNGQPE
HEALHNHYTQ
PGQGLEWMGE
TAVYYCARLG
TSESTAALGC
VVTVPSSNFG
SVFLFPPKPK
TKPREEQFNS
TKGQPREPQV
NNYKTTPPML
KSLSLSPGK
50
100
150
200
250
300
350
400
449
NYLNWYQQKP
EDFATYYCQQ
SVVCLLNNFY
LSKADYEKHK
GKAPKLLIYY 50
GDTLPYTFGG 100
PREAKVQWKV 150
VYACEVTHQG 200
214
Intra-H 22-96 150-206
263-323
369-427
22''-96'' 150''-206'' 263''-323'' 369''-427''
Intra-L 23'-88'
134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 137-214' 137''-214'''
Inter-H-H 225-225'' 226-226'' 229-229'' 232-232''
299, 299''
samidorphanum
samidorphan
17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan3-carboxamide
opioid receptor agonist/antagonist
samidorphan
17-(cyclopropylmthyl)-4,14-dihydroxy-6-oxomorphinane3-carboxamide
agoniste/antagoniste des rcepteurs opiodes
samidorfn
17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida
agonista/antagonista de los receptores de opiceos
852626-89-2
C21H26N2O4
H
HO
H2N
OH
O
434
sapitinibum
sapitinib
2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin6-yl}oxy)piperidin-1-yl]-N-methylacetamide
antineoplastic
sapitinib
2-[4-({4-[(3-chloro-2-fluorophnyl)amino]-7-mthoxyquinazolin6-yl}oxy)pipridin-1-yl]-N-mthylactamide
antinoplasique
sapitinib
2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin6-il}oxi)piperidin-1-il]-N-metilacetamida
antineoplsico
848942-61-0
C23H25ClFN5O3
H3C
CH3
H
N
N
O
N
N
O
HN
sarilumabum #
sarilumab
F
Cl
immunoglobulin G1-kappa, anti-[Homo sapiens IL6R (interleukin 6

receptor, IL-6R, CD126)], Homo sapiens monoclonal antibody;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
immunomodulator
sarilumab
immunoglobuline G1-kappa, anti-[Homo sapiens IL6R (rcepteur de

l'interleukine 6, IL-6R, CD126)], Homo sapiens anticorps
monoclonal;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
immunomodulateur
sarilumab
inmunoglobulina G1-kappa, anti-[Homo sapiens IL6R (receptor de la

interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de Homo
sapiens;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
inmunomodulador
435
1189541-98-7
EVQLVESGGG LVQPGRSLRL SCAASRFTFD
ISWNSGRIGY ADSVKGRFTI SRDNAENSLF
DSFDIWGQGT MVTVSSASTK GPSVFPLAPS
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA
DIQMTQSPSS VSASVGDRVT ITCRASQGIS
ASSLESGVPS RFSGSGSGTD FTLTISSLQP
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA
LSSPVTKSFN RGEC
DYAMHWVRQA
LQMNGLRAED
SKSTSGGTAA
LSSVVTVPSS
PELLGGPSVF
VEVHNAKTKP
IEKTISKAKG
ESNGQPENNY
LHNHYTQKSL
PGKGLEWVSG
TALYYCAKGR
LGCLVKDYFP
SLGTQTYICN
LFPPKPKDTL
REEQYNSTYR
QPREPQVYTL
KTTPPVLDSD
SLSPGK
50
100
150
200
250
300
350
400
446
SWLAWYQQKP
EDFASYYCQQ
SVVCLLNNFY
LSKADYEKHK
GKAPKLLIYG 50
ANSFPYTFGQ 100
PREAKVQWKV 150
VYACEVTHQG 200
214
Intra-H 22-96
143-199
260-320
366-424
22''-96'' 143''-199'' 260''-320'' 366''-424''
Intra-L 23'-88'
134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 219-214' 219''-214'''
Inter-H-H 225-225'' 228-228''
296, 296''
secretinum humanum #
secretin human
human peptide hormone secretin;

L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanylL-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucylL-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminylL-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
diagnostic agent
scrtine humaine
scrtine humaine hormone peptidique;

L-histidyl-L-sryl-L-aspartylglycyl-L-thronyl-L-phnylalanylL-thronyl-L-sryl-L-glutamyl-L-leucyl-L-sryl-L-arginyl-L-leucylL-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminylL-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
produit usage diagnostique
secretina humana
secretina humana, hormona peptdica;

L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-serilL-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicilL-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucilL-glutaminilglicil-L-leucil-L-valinamida
agente de diagnstico
C130H220N44O40
108153-74-8
HSDGTFTSEL SRLREGARLQ RLLQGLV
27

V
27
valinamide
436
NH2
H3C
NH2
CH3
selisistatum
selisistat
rac-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
treatment of Huntington's disease
slisistat
rac-6-chloro-2,3,4,9-ttrahydro-1H-carbazole-1-carboxamide
traitement de la maladie de Huntington
selisistat
rac-6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida
tratamiento de la enfermedad de Huntington
C13H13ClN2O
49843-98-3
H
N
NH2
Cl
setrobuvirum
setrobuvir
and enantiomer
et nantiomre
y enantimero
N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo6
1,4-dihydro-1 ,2,4-benzothiadiazin-7-yl)methanesulfonamide
antiviral
strobuvir
N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophnyl)mthyl]-4-hydroxy-2-oxo1,2,4a,5,6,7,8,8a-octahydro-5,8-mthanoquinolin-3-yl}-1,1-dioxo6
1,4-dihydro-1 ,2,4-benzothiadiazin-7-yl)mthanesulfonamide
antiviral
setrobuvir
N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo1,2,4a,5,6,7,8,8a-octahidro-5,8-metanoquinolin-3-il}-1,1-dioxo6
1,4-dihidro-1 ,2,4-benzotiadiazin-7-il)metanosulfonamida
antiviral
1071517-39-9
C25H25FN4O6S2
F
H
O
H
N
sevuparinum natricum
sevuparin sodium
OH
S
O O
O O
S
N
CH3
H
sodium salt of a low molecular mass heparin obtained by

depolymerization through periodate oxidation of heparin from porcine
intestinal mucosa, followed by reduction and mild acid hydrolysis of
the product; the majority of the components have a 2-amino2-deoxy-D-glucopyranose derivative structure at both ends of their
chain, the one at the reducing end can be substituted with threonic
acid or erythronic acid; the relative average molecular mass range is
approximately 7,500 daltons with about 90% ranging between 2,000
and 15,000 daltons; the degree of sulfation is 2 to 2.5 per
disaccharidic unit
anticoagulant
437
svuparine sodique
sel sodique dune hparine de basse masse molculaire obtenue par

dpolymrisation, au moyen dune oxydation periodique, dhparine
de muqueuse intestinale de porc, suivi par une rduction et par une
hydrolyse douce ; la majorit des composants de la svuparine
sodique possdent une structure 2-amino-2-doxyD-glucopyranose aux deux extrmits, la rductrice peut tre
substitue par un acide thronique ou rythronique ; la masse
molculaire relative moyenne est approximativement de 7500
daltons, et celles de 90% sont comprises entre 2000 15000; le
degr de sulfatation est de 2 2,5 par unit disaccharide.
anticoagulant
sevuparina sdica
sal sdica de una heparina de baja masa molecular obtenida por

despolimerizacin, mediante oxidacin periodica, de heparina de
mucosa intestinal porcina, seguida de reduccin e hidrlisis con
cido dbil ; la mayora de los componentes de la sevuparina sdica
tienen una estructura 2-amino-2-desoxiD-glucopiranosa en los dos extremos, el reductor puede estar
substituido con un cido trenico o eritrnico; la masa molecular
relativa media es aproximadamente de 7500 dalton, y con el 90%
comprendido entre 2000 y 15000; el grado de sulfatacin es de 2 a
2,5 por unidad de disacrido
anticoagulante
9041-08-1
solitomabum #
solitomab
solitomab
438
immunoglobulin scFv-scFv, anti-[Homo sapiens EPCAM (epithelial

cell adhesion molecule, tumor-associated calcium signal transducer
1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2,
epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor
antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[Homo sapiens
CD3E (CD3 epsilon)], Mus musculus monoclonal antibody bispecific
single chain;
scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(tetraglycyl-seryl) linker (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E
[humanized VH (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA
(Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
[5.3.9] (391-496)] -hexahistidine (497-502)
immunomodulator, antineoplastic
immunoglobuline scFv-scFv, anti-[Homo sapiens EPCAM (molcule
d'adhsion des cellules pithliales, transducteur 1 du signal calcium
associ aux tumeurs, TACSTD1, protine 2 associe aux tumeurs
gastrointestinales, GA733-2, glycoprotine pithliale 2, EGP-2,
KSA, antigne KS1/4, M4S1, antigne tumoral 17-1A, Ep-CAM,
EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], Mus
musculus anticorps monoclonal bispcifique chane unique;
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(ttraglycyl-sryl) linker (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer ttraglycyl-sryl linker (249-253) -scFv anti-CD3E [VH
humanis (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01)
[8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (Mus
musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9]
(391-496)] -hexahistidine (497-502)
immunomodulateur, antinoplasique
solitomab
inmunoglobulina scFv-scFv, anti-[EPCAM de Homo sapiens

(molcula de adhesin de clulas epiteliales, transductor 1 de la
seal de calcio asociado a tumores, TACSTD1, proteina 2 asociada
a tumores gastrointestinales, GA733-2, glicoproteina epitelial 2,
EGP-2, KSA, antgeno KS1/4, M4S1, antgeno tumoral 17-1A, EpCAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)],
anticuerpo monoclonal biespecifico monocatenario de Mus
musculus;
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(tetraglicil-seril) conector (114-128) -Mus musculus VH (IGHV154*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH
humanizado (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA
(Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
[5.3.9] (391-496)] -hexahistidina (497-502)
inmunomodulador, antineoplsico
1005198-65-1
ELVMTQSPSS
KLLIYWASTR
PLTFGAGTKL
CKASGYAFTN
ADKSSSTAYM
GGSDVQLVQS
IGYINPSRGY
RYYDDHYCLD
LSLSPGERAT
FSGSGSGTDY
HH
LTVTAGEKVT
ESGVPDRFTG
EIKGGGGSGG
YWLGWVKQRP
QLSSLTFEDS
GAEVKKPGAS
TNYADSVKGR
YWGQGTTVTV
LSCRASQSVS
SLTINSLEAE
MSCKSSQSLL
SGSGTDFTLT
GGSGGGGSEV
GHGLEWIGDI
AVYFCARLRN
VKVSCKASGY
FTITTDKSTS
SSGEGTSTGS
YMNWYQQKPG
DAATYYCQQW
NSGNQKNYLT
ISSVQAEDLA
QLLEQSGAEL
FPGSGNIHYN
WDEPMDYWGQ
TFTRYTMHWV
TAYMELSSLR
GGSGGSGGAD
KAPKRWIYDT
SSNPLTFGGG
WYQQKPGQPP
VYYCQNDYSY
VRPGTSVKIS
EKFKGKATLT
GTTVTVSSGG
RQAPGQGLEW
SEDTATYYCA
DIVLTQSPAT
SKVASGVPAR
TKVEIKHHHH
50
100
150
200
250
300
350
400
450
500
502
Intra-chain 23-94 151-225 275-349 413-477
305 (but Pro in 306)
sovaprevirum
sovaprevir
(2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin4-yl)oxy]pyrrolidine-2-carboxamide
antiviral
sovaprvir
(2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(pipridin-1-yl)butanoyl]N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]2-thnylcyclopropyl}-4-[(7-mthoxy-2-phnylquinolin4-yl)oxy]pyrrolidine-2-carboxamide
antiviral
sovaprevir
(2S,4R)-1-[(2S)-2-terc-butil-4-oxo-4-(piperidin-1-il)butanoil]N-{(1R,2S)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida
antiviral
439
C43H53N5O8S
1001667-23-7
H3CO
H3C
O
CH3
CH3
H
H
N
N
O
sutezolidum
sutezolid
O O
S
N
H
CH2
N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxo1,3-oxazolan-5-yl}methyl)acetamide
antibacterial
sutzolid
N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phnyl]-2-oxo1,3-oxazolidin-5-yl}mthyl)actamide
antibactrien
sutezolid
N-({(5S)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan5-il}metil)acetamida
antibacteriano
C16H20FN3O3S
H H
N
H3C
168828-58-8
O
O
N
O
N
S
tanzisertibum
tanzisertib
(1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophenyl)amino]9H-purin-2-yl}amino)cyclohexan-1-ol
treatment of idiopathic pulmonary fibrosis
tanzisertib
(1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophnyl)amino]9H-purin-2-yl}amino)cyclohexan-1-ol
traitement de la fibrose pulmonaire idiopathique
tanzisertib
(1r,4r)-4-({9-[(3S)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9H-purin2-il}amino)ciclohexan-1-ol
tratamiento de la fibrosis pulmonar idioptica
440
899805-25-5
C21H23F3N6O2
F
F
H
HO
N
N
H H
NH
N
N
H
O
tavaborolum
tavaborole
5-fluoro-2,1-benzoxaborol-1(3H)-ol
antifungal
tavaborole
antifongique
tavaborol
antifngico
174671-46-6
C7H6BFO2
OH
B
O
F
tedatioxetinum
tedatioxetine
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
antidepressant
tdatioxtine
4-{2-[(4-mthylphnyl)sulfanyl]phnyl}pipridine
antidpresseur
tedatioxetina
4-{2-[(4-metilfenil)sulfanil]fenil}piperidina
antidepresivo
C18H21NS
508233-95-2
NH
H3C
tipiracilum
tipiracil
5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine2,4-(1H,3H)-dione
potentiator of antineoplastics
441
tipiracil
5-chloro-6-[(2-iminopyrrolidin-1-yl)mthyl]pyrimidine2,4-(1H,3H)-dione
potentialisateur d'antinoplasiques
tipiracilo
5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1H,3H)-diona
potenciador de antineoplsicos
C9H11ClN4O2
183204-74-2
O
HN
NH
HN
tirasemtivum
tirasemtiv
Cl
6-ethynyl-1-(pentan-3-yl)-2H-imidazo[4,5-b]pyrazin-2-one
troponin activator
tirasemtiv
6-thynyl-1-(pentan-3-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin2-one
activateur de la troponine
tirasemtiv
6-etinil-1-(pentan-3-il)-2H-imidazo[4,5-b]pirazin-2-ona
activador de troponina
C12H14N4O
1005491-05-3
H3C
HC
N
H
CH3
O
tozadenantum
tozadenant
4-hydroxy-N-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]4-methylpiperidine-1-carboxamide
adenosine receptor antagonist
tozadnant
4-hydroxy-N-[4-mthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]4-mthylpipridine-1-carboxamide
antagoniste du rcepteur de l'adnosine
tozadenant
4-hidroxi-N-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]4-metilpiperidina-1-carboxamida
antagonista del receptor de la adenosina
C19H26N4O4S
870070-55-6
O
N
O
N
S
NH
N
OCH3
442
CH3
OH
trebananibum #
trebananib
immunoglobulin G1 Fc fragment fused with two synthetic

polypeptides that bind the Homo sapiens ANGPT2 (angiopoietin 2);
methionyl (1) -gamma1 heavy chain fragment (2-228) [Homo
sapiens IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121),
CH3 (122-228)] fused, at the C-terminal end, with a synthetic
polypeptide that comprises two 14-mer amino acid repeats that bind
angiopoietin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker
(250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')bisdisulfide dimer
angiogenesis inhibitor
trbananib
immunoglobuline G1 fragment Fc fusionn deux polypeptides

synthtiques qui se lient l'Homo sapiens ANGPT2 (angiopotine
2);
mthionyl (1) -fragment de chane gamma1 (2-228) [Homo sapiens
IGHG1*01 charnire (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
(122-228)] fusionn, l'extrmit C-terminale, un polypeptide
synthtique qui comprend deux motifs rpts de 14 acides amins
qui se lient l'angiopotine 2 (229-287) [linker (229-235) -14-mer
(236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate];
dimre (7-7':10-10')-bisdisulfure
inhibiteur de l'angiognse
trebananib
inmunoglobulina G1 fragmento Fc fusionado con dos polipptidos

sintticos que se unen a la ANGPT2 (angiopoyetina 2) de Homo
sapiens;
metionil (1) -fragmento de cadena gamma1 (2-228) [Homo sapiens
IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
(122-228)] fusionada con el extremo C-terminal de un polipptido
sinttico que comprende dos secuencias repetidas de 14
aminocidos que se unen a la angiopoyetina 2 (229-287) [conector
(229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285)
-leucil-glutamato]; dmero (7-7':10-10')-bisdisulfuro
inhibidor de la angiognesis
894356-79-7
MDKTHTCPPC
DPEVKFNWYV
KCKVSNKALP
KGFYPSDIAV
GNVFSCSVMH
SGSATGGSGS
PAPELLGGPS
DGVEVHNAKT
APIEKTISKA
EWESNGQPEN
EALHNHYTQK
TASSGSGSAT
VFLFPPKPKD
KPREEQYNST
KGQPREPQVY
NYKTTPPVLD
SLSLSPGKGG
HQEECEWDPW
TLMISRTPEV
YRVVSVLTVL
TLPPSRDELT
SDGSFFLYSK
GGGAQQEECE
TCEHMLE
TCVVVDVSHE
HQDWLNGKEY
KNQVSLTCLV
LTVDKSRWQQ
WDPWTCEHMG
50
100
150
200
250
287
Intra-chain 42-102 148-206 239-246 275-282
42'-102' 148'-206' 239'-246' 275'-282'
Inter-chains 7-7' 10-10'
78, 78'
trelagliptinum
trelagliptin
trlagliptine
2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl}methyl)-4-fluorobenzonitrile
antidiabetic
2-({6-[(3R)-3-aminopipridin-1-yl]-3-mthyl-2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl}mthyl)-4-fluorobenzonitrile
antidiabtique
443
trelagliptina
2-({6-[(3R)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo3,4-dihidropirimidin-1(2H)-il}metil)-4-fluorobenzonitrilo
hipoglucemiante
865759-25-7
C18H20FN5O2
H
H2N
N
CN
N
CH3
umeclidinii bromidum
umeclidinium bromide
1-{2-[(benzyl)oxy]ethyl}4-[hydroxydi(phenyl)methyl]1-azabicyclo[2.2.2]octan-1-ium bromide
muscarinic receptor antagonist
bromure dumclidinium
bromure de 1-{2-[(benzyl)oxy]thyl}-4-[hydroxydi(phnyl)mthyl]1-azabicyclo[2.2.2]octanium
antagoniste des rcepteurs muscariniques
bromuro de umeclidinio
bromuro de 1-{2-[(bencil)oxi]etil}4-[hidroxidi(fenil)metil]1-azabiciclo[2.2.2]octan-1-io
antagonista de los receptores muscarinicos
869113-09-7
C29H34BrNO2
Br
N
O
OH
vapendavirum
vapendavir
3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}1,2-benzoxazole
antiviral
vapendavir
3-thoxy-6-{2-[1-(6-mthylpyridazin-3-yl)pipridin-4-yl]thoxy}1,2-benzoxazole
antiviral
vapendavir
3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}1,2-benzoxazol
antiviral
439085-51-5
C21H26N4O3
H3C
O N
N
O
444
CH3
vonoprazanum
vonoprazan
1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]N-methylmethanamine
acid pump inhibitor
vonoprazan
1-[5-(2-fluorophnyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]N-mthylmthanamine
inhibiteur de la pompe protons
vonoprazn
1-[5-(2-fluorofenil)-1-(piridina-3-sulfonil)-1H-pirrol-3-il]N-metilmetanamina
inhibidor de la bomba de protones
C17H16FN3O2S
881681-00-1
O
O S
N
CH3
F
vortioxetinum
vortioxetine
NH
1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
antidepressant
vortioxtine
1-{2-[(2,4-dimthylphnyl)sulfanyl]phnyl}piprazine
antidpresseur
vortioxetina
1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina
antidepresivo
C18H22N2S
508233-74-7
N
S
H3C
NH
CH3
# Electronic structure available on Mednet: http://mednet.who.int/

# Structure lectronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrnica disponible en Mednet: http://mednet.who.int/
445
AMENDMENTS TO PREVIOUS LISTS

MODIFICATIONS APPORTES AUX LISTES ANTRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES
Proposed International Non Proprietary Names (Prop. INN): List 6
(Chronicle of the WHO, March 1958, Vol. 12, No. 3)
p. 105
mecamylaminum
mecamylamine
replace the chemical name by the following

(1RS,2SR,4SR)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
Denominations communes internationales proposes (DCI Prop.): Liste 6

(Chronique de l'OMS, Vol. 12, No. 3, mars 1958)
p. 114
mecamylaminum
mcamylamine
remplacer le nom chimique par le suivant

(1RS,2SR,4SR)-N,2,3,3-ttramthylbicyclo[2.2.1]heptan-2-amine
Denominaciones Comunes Internacionales Propuestas (DCI Prop.): Lista 6

(Crnica de la OMS, Vol. 12, No. 3, marzo de 1958)
p. 116
mecamylaminum
mecamilamina
sustityase el nombre qumico por el siguiente

(1RS,2SR,4SR)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina

(WHO Drug Information, Vol. 22, No. 4, 2008)
p. 327
delete/supprimer/suprimse
insert/insrer/insertese
ingenoli mebutatum
ingenoli mebutas

p. 15
beraprostum
beraprost
replace the chemical name and the structure by the following ones
rac-4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4RS)-3-hydroxy-4-methyloct1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran5-yl}butanoic acid
446
CO2H
HO
H
H
its epimer at C* and their enantiomers

son pimre en C* et leurs nantiomres
su epmero al C* y sus enantimeros
HO
CH3
CH3

(Informations pharmaceutiques OMS, Vol. 5, No. 2, 1991)
p. 16
beraprostum
braprost
remplacer le nom chimique et la structure par les suivants

acide rac-4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S,4RS)-3-hydroxy4-mthyloct-1-n-6-ynyl]-2,3,3a,8b-ttrahydro-1H-cyclopenta[b][1]benzofuran5-yl}butanoque
CO2H
HO
H
H

HO
CH3
CH3

(Informacin farmacutica OMS, Vol. 5, No. 2, 1991)
p. 15
beraprostum
beraprost
sustityase el nombre qumico y la estructura por los siguientes

cido rac-4-{(1R,2R,3aS,8bS)-2-hidroxi-1-[(1E,3S,4RS)-3-hidroxi4-metiloct-1-en-6-inil]-2,3,3a,8b-tetrahidro-1H-ciclopenta[b][1]benzofuran5-il}butanoico
CO2H
HO
H
H

HO
H
*
H
CH3
CH3
447

p. 161
olodaterolum
olodaterol
olodatrol
olodaterol

6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropan2-yl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one
6-hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-mthoxyphnyl)-2-mthylpropan2-yl]amino}thyl]-2H-1,4-benzoxazin-3(4H)-one
6-hidroxi-8-[(1R)-1-hidroxi-2-{[1-(4-metoxifenil)-2-metilpropan-2-il]amino}etil]2H-1,4-benzoxazin-3(4H)-ona
p. 166
delete/supprimer/suprimse
insert/insrer/insertese
sograzepidum
sograzepide
sograzpide
sograzepida
netazepidum
netazepide
ntazpide
netazepida

p. 325
condoliasum #
condoliase
condoliase
condoliasa
replace the structure by the following

remplacer la structure par la suivante
sustityase la estructura por la siguiente
ATSNPAFDPK
LLWKWKGGSS
LTIDFGEKLI
TSSDGTQDSI
SDYQVKTRLS
TNLALEENIS
QDKQLFDNYV
DQGFVKGSAL
SREFKSSFDM
HYITGALTQV
DTPFSVGESG
YYWLAMSAKS
FNGGAFGIHR
NGSQLSQGYQ
TSSLEGQYGM
SDKNKNVETT
NGYLITQAEK
YMVFLDATPE
YQPASIEDKW
INVTINGKWQ
448
NLMQSEIYHF
FTLHKKLIVP
STSEAQAGFK
GRSLGAKVDS
EPEIQFHNVK
KLKSDFDALN
ILGNYTTLMF
VTTHHWGYSS
KVSADSSDLD
PPGGKDGLRP
WNNLKKAMVS
SPDKTLASIY
WQDKMVTLKA
QEGWDWNRMQ
MAFDLIYPAN
LFQHAITPTL
VNVSRQHQVS
KMGEMAQKFR
IKKVNKPAIV
SADKNSEVKY
AQNNPLADFS
TDKEASKAWG
VKLDFTGWRA
IRFKAPSNVS
PQLPVTPENL
IHTLANGGTQ
NISRAYVLEK
RWWYISTLLM
YFNTLSRQHL
DGTAWRHEGN
AWIYSNPEVG
LAISDKTQNE
YNTNVWSSEI
GATTIHLPLK
LERFDPNFTA
NTLWINGQKI
AENKNRQPTE
ENNGLYQVLR
MTHRQKDTLI
QVSGDNTELT
SDKNSILTLS
RSSTPVFSFW
VGVSLNNDLE
QGEIYIDRIM
AAIDLIRQRL
GRHLITDKQI
DPTQKAQLKQ
SDALKEANLQ
ALLLLEPDDQ
YPGYSFPAFK
LPLAGRHPFN
STAIFGETIT
YNKDNRYGRY
DLDSPKPHTL
KKSVLAADNH
ENMPYQTTLQ
GNFSSAWIDH
KDKDVHIILD
VSAVTPDLNM
FTSYFGIPQE
DKRSIMGNQS
LYNEKPIDGY
NREMTLNATN
FSVDDARYQW
INEFVGGEKE
IIYQPENLNS
MYLLMTKHLL
TQVYDSLLWY
KRINLVNTFS
NASQLIYLLR
SPSLKSVAQG
PASLPQGFYA
QSHGVAQIVS
MQRGERGFSG
LIFIGSNINS
QGDWLIDSNG
STRPKDASYE
KLSNVTGYAF
TRQKAATPVT
IKLSPLP
50
100
150
200
250
300
350
400
450
500
550
600
650
700
750
800
850
900
950
997

p. 168
encaleretum
encaleret
encalret
encaleret

2-{(1R)-1-[(2R)-3-{[1-(4-chloro-3-fluorophenyl)-2-methylpropan-2-yl]amino}2-hydroxypropoxy]ethyl}-3-methyl[1,1-biphenyl]-4-carboxylic acid
acide 2-{(1R)-1-[(2R)-3-{[1-(4-chloro-3-fluorophnyl)-2-mthylpropan2-yl]amino}-2-hydroxypropoxy]thyl}-3-mthyl[1,1-biphnyl]-4-carboxylique
cido 2-{(1R)-1-[(2R)-3-{[1-(4-cloro-3-fluorofenil)-2-metilpropan-2-il]amino}2-hidroxipropoxi]etil}-3-metil[1,1-bifenil]-4-carboxlico
p. 177
lenomorelinum
lenomorelin
lnomorline
lenomorelina
replace the description and the structure by the following ones

remplacer la description et la structure par les suivantes
sustityase la descripcin y la estructura por las siguientes
3.26
O -octanoylhuman appetite-regulating hormone (growth hormone-releasing

peptide) precursor (protein M46)-(24-51)-peptide (ghrelin-28-C8)
3.26
O -octanoylprcurseur de l'hormone humaine de rgulation de l'apptit

(prcurseur du peptide de libration d'hormone de croissance, protine M46)(24-51)-peptide (ghrline-28-C8)
3.26
O -octanoilprecursor de la hormona humana de regulacin del apetito

(precursor del pptido de liberacin de hormona del crecimiento,
protena M46)-(24-51)-pptido (ghrelina-28-C8)
GSSFLSPEHQ RVQQRKESKK PPAKLQPR
28

S
3
O-octanoyl-L-seryl
O-octanoyl-L-sryl
O-octanoil-L-serilo
O
H
N
H
CH3
C
O
449
p. 188-189
pegnivacoginum
pegnivacogin
pgnivacogin
pegnivacogina
replace the description and the structure by the following

remplacer la description et la structure par les suivantes
sustityase el nombre qumico y la estructura por los siguientes
a ribonucleic acid aptamer which binds Factor XIa;
ester of 2'-O-methyl-5'-O-phosphonoguanylyl-(3'5')-2'-O-methyluridylyl(3' 5')-2'-O-methylguanylyl-(3'5')-2'-O-methylguanylyl-(3'5')-2'-Omethyladenylyl-(3'5')-2'-deoxy-2'-fluorocytidylyl-(3'5')-2'-deoxy-2'fluorouridylyl-(3'5')-2'-O-methyladenylyl-(3'5')-2'-deoxy-2'-fluorouridylyl(3'5')-2'-O-methyladenylyl-(3'5')-2'-deoxy-2'-fluorocytidylyl-(3'5')-2'deoxy-2'-fluorocytidylyl-(3'5')-2'-O-methylguanylyl-(3'5')-2'-deoxy-2'fluorocytidylyl-(3'5')-2'-O-methylguanylyl-(3'5')-2'-deoxy-2'-fluorouridylyl(3'5')-2'-O-methyladenylyl-(3'5')-2'-O-methyladenylyl-(3'5')-2'-deoxy-2'fluorouridylyl-(3'5')-2'-O-methylguanylyl-(3'5')-2'-deoxy-2'-fluorocytidylyl(3'5')-2'-O-methyluridylyl-(3'5')-guanylyl-(3'5')-2'-O-methylcytidylyl(3'5')-2'-deoxy-2'-fluorocytidylyl-(3'5')-2'-deoxy-2'-fluorouridylyl-(3'5')-2'O-methylcytidylyl-(3'5')-2'-O-methylcytidylyl-(3'5')-2'-O-methyladenylyl(3'5')-2'-O-methylcytidylyl-(3'3')-thimidine with 6-[(2,6-bis{N-[methoxypoly(oxyethylene)carbonyl]}-DL-lysyl)amino]hexan-1-ol
acide ribonucleique aptamre se liant au Factor XIa;
ester de 2'-O-mthyl-5'-O-phosphonoguanylyl-(3'5')-2'-O-mthyluridylyl(3'5')-2'-O-mthylguanylyl-(3'5')-2'-O-mthylguanylyl-(3'5')-2'-Omthyladnylyl-(3'5')-2'-doxy-2'-fluorocytidylyl-(3'5')-2'-doxy-2'fluorouridylyl-(3'5')-2'-O-mthyladnylyl-(3'5')-2'-doxy-2'-fluorouridylyl(3'5')-2'-O-mthyladnylyl-(3'5')-2'-doxy-2'-fluorocytidylyl-(3'5')-2'doxy-2'-fluorocytidylyl-(3'5')-2'-O-mthylguanylyl-(3'5')-2'-doxy-2'fluorocytidylyl-(3'5')-2'-O-mthylguanylyl-(3'5')-2'-doxy-2'-fluorouridylyl(3'5')-2'-O-mthyladnylyl-(3'5')-2'-O-mthyladnylyl-(3'5')-2'-doxy-2'fluorouridylyl-(3'5')-2'-O-mthylguanylyl-(3'5')-2'-doxy-2'-fluorocytidylyl(3'5')-2'-O-mthyluridylyl-(3'5')-guanylyl-(3'5')-2'-O-mthylcytidylyl(3'5')-2'-doxy-2'-fluorocytidylyl-(3'5')-2'-doxy-2'-fluorouridylyl-(3'5')-2'O-mthylcytidylyl-(3'5')-2'-O-mthylcytidylyl-(3'5')-2'-O-mthyladnylyl(3'5')-2'-O-mthylcytidylyl-(3'3')-thimidine avec 6-[(2,6-bis{N-[mthoxypoly(oxythylne)carbonyl]}-DL-lysyl)amino]hexan-1-ol
aptmero de cido ribomuclico que se une a Factor XIa;
ster of 2'-O-metil-5'-O-fosfonoguanilil-(3'5')-2'-O-metiluridilil-(3'5')-2'-Ometilguanilil-(3'5')-2'-O-metilguanilil-(3'5')-2'-O-metiladenilil-(3'5')-2'desoxi-2'-fluorocitidilil-(3'5')-2'-desoxi-2'-fluorouridilil-(3'5')-2'-Ometiladenilil-(3'5')-2'-desoxi-2'-fluorouridilil-(3'5')-2'-O-metiladenilil(3'5')-2'-desoxi-2'-fluorocitidilil-(3'5')-2'-desoxi-2'-fluorocitidilil-(3'5')-2'-Ometilguanilil-(3'5')-2'-desoxi-2'-fluorocitidilil-(3'5')-2'-O-metilguanilil(3'5')-2'-desoxi-2'-fluorouridilil-(3'5')-2'-O-metiladenilil-(3'5')-2'-Ometiladenilil-(3'5')-2'-desoxi-2'-fluorouridilil-(3'5')-2'-O-metilguanilil(3'5')-2'-desoxi-2'-fluorocitidilil-(3'5')-2'-O-metiluridilil-(3'5')-guanilil(3'5')-2'-O-metilcitidilil-(3'5')-2'-desoxi-2'-fluorocitidilil-(3'5')-2'-desoxi-2'fluorouridilil-(3'5')-2'-O-metilcitidilil-(3'5')-2'-O-metilcitidilil-(3'5')-2'-Ometiladenilil-(3'5')-2'-O-metilcitidilil-(3'3')-timidina con 6-[(2,6-bis{N-[metoxipoli(oxietileno)carbonil]}-DL-lisil)amino]hexan-1-ol
450
(3'-5')-R-pmG-mU-mG-mG-mA-dflC-dflU-mA-dflU-mA-dflC-dflC-mGdflC-mG-dflU-mA-mA-dflU-mG-dflC-mU-G-mC-dflC-dflU-mC-mC-mA-mC3'-3'dT
Legend:
dfl = 2'-deoxy-2'-fluoro ; m = 2'-O-methyl ; p (as prefix) = 5'-phosphate
O
R- =
N
H
x+y=n
O
H 3C
p. 193
siponimodum
siponimod
siponimod
siponimod
N
x H
H
N
O
y
CH3
CH2
replace the CASRN by the following

remplacer le numro de registre du CAS par le suivant
sustityase el Nmero de registro del CAS por el siguiente
1230487-00-9
451
ANNEX 1
PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL

NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1
The following procedure shall be followed by the World Health Organization (hereinafter also referred to as WHO)
in the selection of recommended international nonproprietary names for pharmaceutical substances, in accordance with
resolution WHA3.11 of the World Health Assembly, and in the substitution of such names.
Article 1 - Proposals for recommended international nonproprietary names and proposals for substitution of such names
shall be submitted to WHO on the form provided therefore. The consideration of such proposals shall be subject to the
payment of an administrative fee designed only to cover the corresponding costs of the Secretariat of WHO (the
Secretariat). The amount of this fee shall be determined by the Secretariat and may, from time to time, be adjusted.
Article 2 - Such proposals shall be submitted by the Secretariat to the members of the Expert Advisory Panel on the
International Pharmacopoeia and Pharmaceutical Preparations designated for this purpose, such designated members
hereinafter referred to as the INN Expert Group, for consideration in accordance with the General principles for guidance
2
in devising International Nonproprietary Names for Pharmaceutical Substances, annexed to this procedure . The name
used by the person discovering or first developing and marketing a pharmaceutical substance shall be accepted, unless
there are compelling reasons to the contrary.
Article 3 - Subsequent to the examination provided for in article 2, the Secretariat shall give notice that a proposed
international nonproprietary name is being considered.
3
a) Such notice shall be given by publication in WHO Drug Information and by letter to Member States and to national and
regional pharmacopoeia commissions or other bodies designated by Member States.
i) Notice shall also be sent to the person who submitted the proposal (the original applicant) and other persons
known to be concerned with a name under consideration.
b) Such notice shall:
i) set forth the name under consideration;
ii) identify the person who submitted the proposal for naming the substance, if so requested by such person;
iii) identify the substance for which a name is being considered;
iv) set forth the time within which comments and objections will be received and the person and place to whom
they should be directed;
v) state the authority under which WHO is acting and refer to these rules of procedure.
c) In forwarding the notice, the Secretariat shall request that Member States take such steps as are necessary to prevent
the acquisition of proprietary rights in the proposed name during the period it is under consideration by WHO.
Article 4 - Comments on the proposed name may be forwarded by any person to WHO within four months of the date of
publication, under article 3, of the name in WHO Drug Information.
1
See Annex 1 in WHO Technical Report Series, No. 581, 1975. The original text was adopted by the Executive Board in resolution EB15.R7 and amended
in resolutions EB43.R9 and EB115.R4.
452
See Annex 2.
Before 1987, lists of international nonproprietary names were published in the Chronicle of the World Health Organization.
Article 5 - A formal objection to a proposed name may be filed by any interested person within four months of the date of
publication, under article 3, of the name in WHO Drug Information.
Such objection shall:
i) identify the person objecting;
ii) state his or her interest in the name;
iii) set forth the reasons for his or her objection to the name proposed.
Article 6 - Where there is a formal objection under article 5, WHO may either reconsider the proposed name or use its good
offices to attempt to obtain withdrawal of the objection. Without prejudice to the consideration by WHO of a substitute name
or names, a name shall not be selected by WHO as a recommended international nonproprietary name while there exists a
formal objection thereto filed under article 5 which has not been withdrawn.
Article 7 - Where no objection has been filed under article 5, or all objections previously filed have been withdrawn, the
Secretariat shall give notice in accordance with subsection (a) of article 3 that the name has been selected by WHO as a
recommended international nonproprietary name.
Article 8 - In forwarding a recommended international nonproprietary name to Member States under article 7, the Secretariat
shall:
a) request that it be recognized as the nonproprietary name for the substance; and
b) request that Member States take such steps as are necessary to prevent the acquisition of proprietary rights in the name
and to prohibit registration of the name as a trademark or trade name.
Article 9
a) In the extraordinary circumstance that a previously recommended international nonproprietary name gives rise to errors
in medication, prescription or distribution, or a demonstrable risk thereof, because of similarity with another name in
pharmaceutical and/or prescription practices, and it appears that such errors or potential errors cannot readily be resolved
through other interventions than a possible substitution of a previously recommended international nonproprietary name, or
in the event that a previously recommended international nonproprietary name differs substantially from the nonproprietary
name approved in a significant number of Member States, or in other such extraordinary circumstances that justify a
substitution of a recommended international nonproprietary name, proposals to that effect may be filed by any interested
person. Such proposals shall be submitted on the form provided therefore and shall:
i) identify the person making the proposal;
ii) state his or her interest in the proposed substitution; and
iii) set forth the reasons for the proposal; and
iv) describe, and provide documentary evidence regarding the other interventions undertaken in an effort to
resolve the situation, and the reasons why these other interventions were inadequate.
Such proposals may include a proposal for a new substitute international nonproprietary name, devised in accordance with
the General principles, which takes into account the pharmaceutical substance for which the new substitute international
nonproprietary name is being proposed.
The Secretariat shall forward a copy of the proposal, for consideration in accordance with the procedure described in
subsection (b) below, to the INN Expert Group and the original applicant or its successor (if different from the person
bringing the proposal for substitution and provided that the original applicant or its successor is known or can be found
through diligent effort, including contacts with industry associations).
In addition, the Secretariat shall request comments on the proposal from:
i) Member States and national and regional pharmacopoeia commissions or other bodies designated by Member
States (by including a notice to that effect in the letter referred to in article 3(a), and
ii) any other persons known to be concerned by the proposed substitution.
453
The request for comments shall:

i) state the recommended international nonproprietary name that is being proposed for substitution (and the
proposed substitute name, if provided);
ii) identify the person who submitted the proposal for substitution (if so requested by such person);
iii) identify the substance to which the proposed substitution relates and reasons put forward for substitution;
iv) set forth the time within which comments will be received and the person and place to whom they should be
directed; and
v) state the authority under which WHO is acting and refer to these rules of procedure.
Comments on the proposed substitution may be forwarded by any person to WHO within four months of the date of the
request for comments.
b) After the time period for comments referred to above has elapsed, the Secretariat shall forward any comments received
to the INN Expert Group, the original applicant or its successor and the person bringing the proposal for substitution. If, after
consideration of the proposal for substitution and the comments received, the INN Expert Group, the person bringing the
proposal for substitution and the original applicant or its successor all agree that there is a need to substitute the previously
recommended international nonproprietary name, the Secretariat shall submit the proposal for substitution to the INN Expert
Group for further processing.
Notwithstanding the foregoing, the original applicant or its successor shall not be entitled to withhold agreement to a
proposal for substitution in the event the original applicant or its successor has no demonstrable continuing interest in the
recommended international nonproprietary name proposed for substitution.
In the event that a proposal for substitution shall be submitted to the INN Expert Group for further processing, the
INN Expert Group will select a new international nonproprietary name in accordance with the General principles referred to
in article 2 and the procedure set forth in articles 3 to 8 inclusive. The notices to be given by the Secretariat under article 3
and article 7, respectively, including to the original applicant or its successor (if not the same as the person proposing the
substitution, and provided that the original applicant or its successor is known or can be found through diligent effort,
including contacts with industry associations), shall in such event indicate that the new name is a substitute for a previously
recommended international nonproprietary name and that Member States may wish to make transitional arrangements in
order to accommodate existing products that use the previously recommended international nonproprietary name on their
label in accordance with national legislation.
If, after consideration of the proposal for substitution and the comments received in accordance with the
procedure described above, the INN Expert Group, the original applicant or its successor and the person bringing the
proposal for substitution do not agree that there are compelling reasons for substitution of a previously recommended
international nonproprietary name, this name shall be retained (provided always that the original applicant or its successor
shall not be entitled to withhold agreement to a proposal for substitution in the event that the original applicant or its
successor has no demonstrable continuing interest in the recommended international nonproprietary name proposed to be
substituted). In such an event, the Secretariat shall advise the person having proposed the substitution, as well as the
original applicant or its successor (if not the same as the person proposing the substitution, and provided that the original
applicant or its successor is known or can be found through diligent effort, including contacts with industry associations),
Member States, national and regional pharmacopoeia commissions, other bodies designated by Member States, and any
other persons known to be concerned by the proposed substitution that, despite a proposal for substitution, it has been
decided to retain the previously recommended international nonproprietary name (with a description of the reason(s) why
the proposal for substitution was not considered sufficiently compelling).
454
ANNEX 2
GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL

NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES1
1. International Nonproprietary Names (INN) should be distinctive in sound and spelling. They should not be inconveniently
long and should not be liable to confusion with names in common use.
2. The INN for a substance belonging to a group of pharmacologically related substances should, where appropriate, show
this relationship. Names that are likely to convey to a patient an anatomical, physiological, pathological or therapeutic
suggestion should be avoided.
These primary principles are to be implemented by using the following secondary principles:
3. In devising the INN of the first substance in a new pharmacological group, consideration should be given to the possibility
of devising suitable INN for related substances, belonging to the new group.
4. In devising INN for acids, one-word names are preferred; their salts should be named without modifying the acid name,
e.g. oxacillin and oxacillin sodium, ibufenac and ibufenac sodium.
5. INN for substances which are used as salts should in general apply to the active base or the active acid. Names for
different salts or esters of the same active substance should differ only in respect of the name of the inactive acid or the
inactive base.
For quaternary ammonium substances, the cation and anion should be named appropriately as separate components of a
quaternary substance and not in the amine-salt style.
6. The use of an isolated letter or number should be avoided; hyphenated construction is also undesirable.
7. To facilitate the translation and pronunciation of INN, f should be used instead of ph, t instead of th, e instead of
ae or oe, and i instead of y; the use of the letters h and k should be avoided.
8. Provided that the names suggested are in accordance with these principles, names proposed by the person discovering
or first developing and marketing a pharmaceutical preparation, or names already officially in use in any country, should
receive preferential consideration.
9. Group relationship in INN (see General principle 2) should if possible be shown by using a common stem. The following
list contains examples of stems for groups of substances, particularly for new groups. There are many other stems in active
2
use. Where a stem is shown without any hyphens it may be used anywhere in the name.
Latin
-acum
-adolum
-adol-astum
-astinum
-azepamum
bol
-cain-cainum
English
-ac
-adol }
-adol-}
-ast
-astine
-azepam
bol
-cain-caine
anti-inflammatory agents, ibufenac derivatives

analgesics
antiasthmatic, antiallergic substances not acting primarily as antihistaminics
antihistaminics
diazepam derivatives
steroids, anabolic
class I antiarrhythmics, procainamide and lidocaine derivatives
local anaesthetics
In its Twentieth report (WHO Technical Report Series, No. 581, 1975), the WHO Expert committee on Nonproprietary Names for Pharmaceutical Substances
reviewed the general principles for devising, and the procedures for selecting, INN in the light of developments in pharmaceutical compounds in recent years. The
most significant change has been the extension to the naming of synthetic chemical substances of the practice previously used for substances originating in or
derived from natural products. This practice involves the use of a characteristic stem indicative of a common property of the members of a group. The reason for,
and the implications of, the change are fully discussed.
th
The guiding principles were updated during the 13 consultation on nonproprietary names for pharmaceutical substances (Geneva, 27-29 April 1983) (PHARM
S/NOM 928 13 May 1983, revised 18 August 1983).
2
A more extensive listing of stems is contained in the working document WHO/EMP/QSM/2009.3 which is regularly updated and can be requested from the INN
Programme, WHO, Geneva.
455
cef-cillinum
-conazolum
cort
-coxibum
-entanum
gab
gado-gatranum
gest
gli
io-metacinum
-mycinum
-nidazolum
-ololum
-oxacinum
-platinum
-poetinum
-pril(at)um
-profenum
prost
-relinum
-sartanum
-vaptanum
vin-vin-
cef-cillin
-conazole
cort
-coxib
-entan
gab
gado-gatran
gest
gli
io-metacin
-mycin
-nidazole
-olol
-oxacin
-platin
-poetin
-pril(at)
-profen
prost
-relin
-sartan
-vaptan
vin- }
-vin-}
antibiotics, cefalosporanic acid derivatives

antibiotics, 6-aminopenicillanic acid derivatives
systemic antifungal agents, miconazole derivatives
corticosteroids, except prednisolone derivatives
selective cyclo-oxygenase inhibitors
endothelin receptor antagonists
gabamimetic agents
diagnostic agents, gadolinium derivatives
thrombin inhibitors, antithrombotic agents
steroids, progestogens
antihyperglycaemics
iodine-containing contrast media
anti-inflammatory, indometacin derivatives
antibiotics, produced by Streptomyces strains
antiprotozoals and radiosensitizers, metronidazole derivatives
-adrenoreceptor antagonists
antibacterial agents, nalidixic acid derivatives
antineoplastic agents, platinum derivatives
erythropoietin type blood factors
angiotensin-converting enzyme inhibitors
anti-inflammatory agents, ibuprofen derivatives
prostaglandins
pituitary hormone release-stimulating peptides
angiotensin II receptor antagonists, antihypertensive (non-peptidic)
vasopressin receptor antagonists
vinca-type alkaloids
ANNEXE 1
PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES

INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES
PHARMACEUTIQUES1
LOrganisation mondiale de la Sant (galement dsigne ci-aprs sous lappellation OMS ) observe la procdure
expose ci-dessous pour lattribution de dnominations communes internationales recommandes pour les substances
pharmaceutiques, conformment la rsolution WHA3.11 de lAssemble mondiale de la Sant, et pour le remplacement
de telles dnominations.
Article 1 - Les propositions de dnominations communes internationales recommandes et les propositions de
remplacement de telles dnominations sont soumises lOMS sur la formule prvue cet effet. Lexamen de telles
propositions est soumis au paiement dune taxe administrative destine uniquement couvrir les cots correspondants
assums par le Secrtariat de lOMS ( le Secrtariat ). Le montant de cette taxe est dtermin par le Secrtariat et peut
tre modifi de temps autre.
Article 2 - Ces propositions sont soumises par le Secrtariat aux experts dsigns cette fin parmi les personnalits
inscrites au Tableau dexperts de la Pharmacope internationale et des Prparations pharmaceutiques, ci-aprs dsigns
sous lappellation le Groupe dexperts des DCI ; elles sont examines par les experts conformment aux Directives
gnrales pour la formation de dnominations communes internationales pour les substances pharmaceutiques
2
reproduites ci-aprs . La dnomination accepte est la dnomination employe par la personne qui dcouvre ou qui, la
premire, fabrique et lance sur le march une substance pharmaceutique, moins que des raisons majeures nobligent
scarter de cette rgle.
1
Voir annexe 1 dans OMS, Srie de Rapports techniques, N 581, 1975. Le texte original a t adopt par le Conseil excutif dans sa rsolution EB15.R7
et amend dans ses rsolutions EB43.R9 et EB115.R4.
2
456
Voir annexe 2.
Article 3 - Aprs lexamen prvu larticle 2, le Secrtariat notifie quun projet de dnomination commune internationale est
ltude.
1
a) Cette notification est faite par une insertion dans WHO Drug Information et par lenvoi dune lettre aux Etats Membres et
aux commissions nationales et rgionales de pharmacope ou autres organismes dsigns par les Etats Membres.
i) Notification est galement faite la personne qui a soumis la proposition ( le demandeur initial ) et dautres
personnes portant la dnomination mise ltude un intrt notoire.
b) Cette notification contient les indications suivantes :
i) dnomination mise ltude;
ii) nom de lauteur de la proposition tendant attribuer une dnomination la substance, si cette personne le
demande ;
iii) dfinition de la substance dont la dnomination est mise ltude ;
iv) dlai pendant lequel seront reues les observations et les objections lgard de cette dnomination ; nom et
adresse de la personne habilite recevoir ces observations et objections ;
v) mention des pouvoirs en vertu desquels agit lOMS et rfrence au prsent rglement.
c) En envoyant cette notification, le Secrtariat demande aux Etats Membres de prendre les mesures ncessaires pour
prvenir lacquisition de droits de proprit sur la dnomination propose pendant la priode au cours de laquelle cette
dnomination est mise ltude par lOMS.
Article 4 - Des observations sur la dnomination propose peuvent tre adresses lOMS par toute personne, dans les
quatre mois qui suivent la date de publication de la dnomination dans WHO Drug Information (voir larticle 3).
Article 5 - Toute personne intresse peut formuler une objection formelle contre la dnomination propose dans les quatre
mois qui suivent la date de publication de la dnomination dans WHO Drug Information (voir larticle 3).
Cette objection doit saccompagner des indications suivantes :
i) nom de lauteur de lobjection ;
ii) intrt quil ou elle porte la dnomination en cause ;
iii) raisons motivant lobjection contre la dnomination propose.
Article 6 - Lorsquune objection formelle est formule en vertu de larticle 5, lOMS peut soit soumettre la dnomination
propose un nouvel examen, soit intervenir pour tenter dobtenir le retrait de lobjection. Sans prjudice de lexamen par
lOMS dune ou de plusieurs appellations de remplacement, lOMS nadopte pas dappellation comme dnomination
commune internationale recommande tant quune objection formelle prsente conformment larticle 5 nest pas leve.
Article 7 - Lorsquil nest formul aucune objection en vertu de larticle 5, ou que toutes les objections prsentes ont t
leves, le Secrtariat fait une notification conformment aux dispositions du paragraphe a) de larticle 3, en indiquant que la
dnomination a t choisie par lOMS en tant que dnomination commune internationale recommande.
Article 8 - En communiquant aux Etats Membres, conformment larticle 7, une dnomination commune internationale
recommande, le Secrtariat :
a) demande que cette dnomination soit reconnue comme dnomination commune de la substance considre ; et
b) demande aux Etats Membres de prendre les mesures ncessaires pour prvenir lacquisition de droits de proprit sur
cette dnomination et interdire le dpt de cette dnomination comme marque ou appellation commerciale.
Avant 1987, les listes de dnominations communes internationales taient publies dans la Chronique de lOrganisation mondiale de la Sant.
457
Article 9 a) Dans le cas exceptionnel o une dnomination commune internationale dj recommande donne lieu des erreurs de
mdication, de prescription ou de distribution ou en comporte un risque dmontrable, en raison dune similitude avec une
autre appellation dans la pratique pharmaceutique et/ou de prescription, et o il apparat que ces erreurs ou ces risques
derreur ne peuvent tre facilement vits par dautres interventions que le remplacement ventuel dune dnomination
commune internationale dj recommande, ou dans le cas o une dnomination commune internationale dj
recommande diffre sensiblement de la dnomination commune approuve dans un nombre important dEtats Membres,
ou dans dautres circonstances exceptionnelles qui justifient le remplacement dune dnomination commune internationale
recommande, toute personne intresse peut formuler une proposition dans ce sens. Cette proposition est prsente sur
la formule prvue cet effet et doit saccompagner des indications suivantes :
i) nom de lauteur de la proposition ;
ii) intrt quil ou elle porte au remplacement propos ;
iii) raisons motivant la proposition ; et
iv) description, faits lappui, des autres interventions entreprises pour tenter de rgler le problme et expos des
raisons pour lesquelles ces interventions ont chou.
Les propositions peuvent comprendre une proposition de nouvelle dnomination commune internationale de remplacement,
tablie conformment aux Directives gnrales, compte tenu de la substance pharmaceutique pour laquelle la nouvelle
dnomination commune internationale de remplacement est propose.
Le Secrtariat transmet une copie de la proposition pour examen, conformment la procdure expose plus loin au
paragraphe b), au Groupe dexperts des DCI et au demandeur initial ou son successeur (sil sagit dune personne
diffrente de celle qui a formul la proposition de remplacement et pour autant que le demandeur initial ou son successeur
soit connu ou puisse tre retrouv moyennant des efforts diligents, notamment des contacts avec les associations
industrielles).
De plus, le Secrtariat demande aux entits et personnes ci-aprs de formuler des observations sur la proposition :
i) les Etats Membres et les commissions nationales et rgionales de pharmacope ou dautres organismes
dsigns par les Etats Membres (en insrant une note cet effet dans la lettre mentionne larticle 3.a), et
ii) toutes autres personnes portant au remplacement propos un intrt notoire.
La demande dobservations contient les indications suivantes :
i) dnomination commune internationale recommande pour laquelle un remplacement est propos (et la
dnomination de remplacement propose, si elle est fournie) ;
ii) nom de lauteur de la proposition de remplacement (si cette personne le demande) ;
iii) dfinition de la substance faisant lobjet du remplacement propos et raisons avances pour le remplacement ;
iv) dlai pendant lequel seront reus les commentaires et nom et adresse de la personne habilite recevoir ces
commentaires ; et
v) mention des pouvoirs en vertu desquels agit lOMS et rfrence au prsent rglement.
Des observations sur la proposition de remplacement peuvent tre communiques par toute personne lOMS dans les
quatre mois qui suivent la date de la demande dobservations.
b) Une fois chu le dlai prvu ci-dessus pour la communication dobservations, le Secrtariat transmet les observations
reues au Groupe dexperts des DCI, au demandeur initial ou son successeur et lauteur de la proposition de
remplacement. Si, aprs avoir examin la proposition de remplacement et les observations reues, le Groupe dexperts des
DCI, lauteur de la proposition de remplacement et le demandeur initial ou son successeur reconnaissent tous quil est
ncessaire de remplacer la dnomination commune internationale dj recommande, le Secrtariat soumet la proposition
de remplacement au Groupe dexperts des DCI pour quil y donne suite.
458
Nonobstant ce qui prcde, le demandeur initial ou son successeur nest pas habilit refuser son accord une
proposition de remplacement au cas o il ne peut tre dmontr quil porte un intrt durable la dnomination commune
internationale recommande quil est propos de remplacer.
Dans le cas o une proposition de remplacement est soumise au Groupe dexperts des DCI pour quil y donne
suite, le Groupe choisit une nouvelle dnomination commune internationale conformment aux Directives gnrales
mentionnes larticle 2 et selon la procdure dcrite dans les articles 3 8 inclus. La notification faite par le Secrtariat en
vertu de larticle 3 et de larticle 7, respectivement, y compris au demandeur initial ou son successeur (si ce nest pas la
mme personne que celle qui a propos le remplacement et pour autant que le demandeur initial ou son successeur soit
connu ou puisse tre retrouv moyennant des efforts diligents, notamment des contacts avec les associations industrielles),
doit dans un tel cas indiquer que la nouvelle dnomination remplace une dnomination commune internationale dj
recommande et que les Etats Membres peuvent souhaiter prendre des mesures transitoires pour les produits existants qui
utilisent la dnomination commune internationale dj recommande sur leur tiquette conformment la lgislation
nationale.
Si, aprs examen de la proposition de remplacement et des observations communiques conformment la
procdure expose plus haut, le Groupe dexperts des DCI, le demandeur initial ou son successeur et lauteur de la
proposition de remplacement ne saccordent pas sur le fait quil y a des raisons impratives de remplacer une
dnomination commune internationale dj recommande, cette dernire est conserve (tant entendu toujours que le
demandeur initial ou son successeur nest pas habilit refuser son accord une proposition de remplacement au cas o il
ne peut tre dmontr quil porte un intrt durable la dnomination commune internationale recommande quil est
propos de remplacer). Dans un tel cas, le Secrtariat informe lauteur de la proposition de remplacement, ainsi que le
demandeur initial ou son successeur (sil sagit dune personne diffrente de celle qui a formul la proposition de
remplacement et pour autant que le demandeur initial ou son successeur soit connu ou puisse tre retrouv moyennant des
efforts diligents, notamment des contacts avec les associations industrielles), les Etats Membres, les commissions
nationales et rgionales de pharmacope, les autres organismes dsigns par les Etats Membres et toutes autres
personnes portant un intrt notoire au remplacement propos que, malgr une proposition de remplacement, il a t
dcid de conserver la dnomination commune internationale dj recommande (avec une brve description de la ou des
raisons pour lesquelles la proposition de remplacement na pas t juge suffisamment imprative).
ANNEXE 2
DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS

COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES
PHARMACEUTIQUES1
1. Les dnominations communes internationales (DCI) devront se distinguer les unes des autres par leur consonance et
leur orthographe. Elles ne devront pas tre dune longueur excessive, ni prter confusion avec des appellations dj
couramment employes.
2. La DCI de chaque substance devra, si possible, indiquer sa parent pharmacologique. Les dnominations susceptibles
dvoquer pour les malades des considrations anatomiques, physiologiques, pathologiques ou thrapeutiques devront tre
vites dans la mesure du possible.
Outre ces deux principes fondamentaux, on respectera les principes secondaires suivants :
Lorsquon formera la DCI de la premire substance dun nouveau groupe pharmacologique, on tiendra compte de la
possibilit de former ultrieurement dautres DCI appropries pour les substances apparentes du mme groupe.
Dans son vingtime rapport (OMS, Srie de Rapports techniques, N 581, 1975), le Comit OMS dexperts des Dnominations communes pour les Substances
pharmaceutiques a examin les directives gnrales pour la formation des dnominations communes internationales et la procdure suivre en vue de leur choix,
compte tenu de lvolution du secteur pharmaceutique au cours des dernires annes. La modification la plus importante a t lextension aux substances de
synthse de la pratique normalement suivie pour dsigner les substances tires ou drives de produits naturels. Cette pratique consiste employer des syllabes
communes ou groupes de syllabes communes (segments-cls) qui sont caractristiques et indiquent une proprit commune aux membres du groupe des
substances pour lequel ces segments-cls ont t retenus. Les raisons et les consquences de cette modification ont fait lobjet de discussions approfondies.
Les directives ont t mises jour lors de la treizime consultation sur les dnominations communes pour les substances pharmaceutiques (Genve, 27-29 avril
1983) (PHARM S/NOM 928, 13 mai 1983, rvision en date du 18 aot 1983).
459
4. Pour former des DCI des acides, on utilisera de prfrence un seul mot. Leurs sels devront tre dsigns par un terme
qui ne modifie pas le nom de lacide dorigine : par exemple oxacilline et oxacilline sodique, ibufnac et ibufnac
sodique.
5. Les DCI pour les substances utilises sous forme de sels devront en gnral sappliquer la base active (ou lacide
actif). Les dnominations pour diffrents sels ou esters dune mme substance active ne diffreront que par le nom de
lacide inactif (ou de la base inactive).
En ce qui concerne les substances base dammonium quaternaire, la dnomination sappliquera de faon approprie au
cation et lanion en tant qulments distincts dune substance quaternaire. On vitera de choisir une dsignation
voquant un sel amin.
6. On vitera dajouter une lettre ou un chiffre isol ; en outre, on renoncera de prfrence au trait dunion.
7. Pour simplifier la traduction et la prononciation des DCI, la lettre f sera utilise la place de ph , t la place de
th , e la place de ae ou oe , et i la place de y ; lusage des lettres h et k sera aussi vit.
8. On retiendra de prfrence, pour autant quelles respectent les principes noncs ici, les dnominations proposes par
les personnes qui ont dcouvert ou qui, les premires, ont fabriqu et lanc sur le march les prparations
pharmaceutiques considres, ou les dnominations dj officiellement adoptes par un pays.
9. La parent entre substances dun mme groupe (voir Directive gnrale 2) sera si possible indique dans les DCI par
lemploi de segments-cls communs. La liste ci-aprs contient des exemples de segments-cls pour des groupes de
1
substances, surtout pour des groupes rcents. Il y a beaucoup dautres segments-cls en utilisation active. Les segmentscls indiqus sans trait dunion pourront tre insrs nimporte o dans une dnomination.
Latin
Franais
-acum
-adolum
-adol-astum
-ac
-adol
-adol-ast
-astinum
-azepamum
bol
-cain-cainum
cef-cillinum
-conazolum
cort
-coxibum
-entanum
gab
gado-gatranum
gest
gli
io-metacinum
-mycinum
-nidazolum
-ololum
-oxacinum
-platinum
-poetinum
-pril(at)um
-profenum
prost
-astine
-azpam
bol
-can-cane
cf-cilline
-conazole
cort
-coxib
-entan
gab
gado-gatran
gest
gli
io-mtacine
-mycine
-nidazole
-olol
-oxacine
-platine
-potine
-pril(ate)
-profne
prost
}
}
substances anti-inflammatoires du groupe de libufnac

analgsiques
antiasthmatiques, antiallergiques nagissant pas principalement en tant
quantihistaminiques
antihistaminiques
substances du groupe du diazpam
strodes anabolisants
antiarythmiques de classe I, drivs du procanamide et de la lidocane
anesthsiques locaux
antibiotiques, drivs de lacide cphalosporanique
antibiotiques, drivs de lacide 6-aminopnicillanique
agents antifongiques systmiques du groupe du miconazole
corticostrodes, autres que les drivs de la prednisolone
inhibiteurs slectifs de la cyclo-oxygnase
antagonistes du rcepteur de lendothline
gabamimtiques
agents diagnostiques, drivs du gadolinium
antithrombines, antithrombotiques
strodes progestognes
antihyperglycmiants
produits de contraste iods
anti-inflammatoires du groupe de lindomtacine
antibiotiques produits par des souches de Streptomyces
antiprotozoaires et radiosensibilisants du groupe du mtronidazole
antagonistes des rcepteurs -adrnergiques
substances antibactriennes du groupe de lacide nalidixique
antinoplasiques, drivs du platine
facteurs sanguins de type rythropotine
inhibiteurs de lenzyme de conversion de langiotensine
anti-inflammatoires du groupe de libuprofne
prostaglandines
Une liste plus complte de segments-cls est contenue dans le document de travail WHO/EMP/QSM/2009.3 qui est rgulirement mis jour et qui peut tre
demand auprs du programme des DCI, OMS, Genve.
460
-relinum
-sartanum
-rline
-sartan
-vaptanum
vin-vin-
-vaptan
vin-vin-
}
}
peptides stimulant la libration dhormones hypophysaires

antagonistes dun rcepteur de langiotensine II, antihypertenseurs (non
peptidiques)
antagonistes du rcepteur de la vasopressine
alcalodes du type vinca
ANEXO 1
PROCEDIMIENTO DE SELECCIN DE DENOMINACIONES COMUNES

INTERNACIONALES RECOMENDADAS PARA SUSTANCIAS FARMACUTICAS1
La Organizacin Mundial de la Salud (OMS) seguir el procedimiento que se expone a continuacin tanto para seleccionar
denominaciones comunes internacionales recomendadas para las sustancias farmacuticas, de conformidad con lo
dispuesto en la resolucin WHA3.11, como para sustituir esas denominaciones.
Artculo 1 - Las propuestas de denominaciones comunes internacionales recomendadas y las propuestas de sustitucin de
esas denominaciones se presentarn a la OMS en los formularios que se proporcionen a estos efectos. El estudio de estas
propuestas estar sujeto al pago de una tasa destinada a sufragar los costos de administracin que ello suponga para la
Secretara de la OMS (la Secretara). La Secretara establecer la cuanta de esa tasa y podr ajustarla peridicamente.
Artculo 2 - Estas propuestas sern sometidas por la Secretara a los miembros del Cuadro de Expertos en Farmacopea
Internacional y Preparaciones Farmacuticas encargados de su estudio, en adelante designados como el Grupo de
Expertos en DCI, para que las examinen de conformidad con los Principios generales de orientacin para formar
2
denominaciones comunes internacionales para sustancias farmacuticas, anexos a este procedimiento. A menos que
haya poderosas razones en contra, la denominacin aceptada ser la empleada por la persona que haya descubierto o
fabricado y comercializado por primera vez esa sustancia farmacutica.
Artculo 3 - Tras el examen al que se refiere el artculo 2, la Secretara notificar que est en estudio un proyecto de
denominacin internacional.
3
a) Esa notificacin se har mediante una publicacin en Informacin Farmacutica OMS y el envo de una carta a los
Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos designados por los
Estados Miembros.
i) La notificacin ser enviada tambin a la persona que haya presentado la propuesta (el solicitante inicial) y a
otras personas que tengan un inters especial en una denominacin objeto de estudio.
b) En esa notificacin se incluirn los siguientes datos:
i) la denominacin sometida a estudio;
ii) la identidad de la persona que ha presentado la propuesta de denominacin de la
sustancia, si lo pide esa persona;
iii) la identidad de la sustancia cuya denominacin est en estudio;
iv) el plazo fijado para recibir observaciones y objeciones, as como el nombre y la direccin de la persona a
quien deban dirigirse; y
v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.
Vase el anexo 1 en OMS, Serie de Informes Tcnicos, N 581, 1975. El texto vigente fue adoptado por el Consejo Ejecutivo en su resolucin EB15.R7 y
modificado en las resolucines EB43.R9 y EB115.R4..
Vase el anexo 2.
Hasta 1987 las listas de DCI se publicaban en la Crnica de la Organizacin Mundial de la Salud.
461
c) Al enviar esa notificacin, la Secretara solicitar de los Estados Miembros la adopcin de todas las medidas necesarias
para impedir la adquisicin de derechos de patente sobre la denominacin propuesta, durante el periodo en que la OMS la
tenga en estudio.
Artculo 4 - Toda persona puede formular a la OMS observaciones sobre la denominacin propuesta dentro de los cuatro
meses siguientes a su publicacin en Informacin Farmacutica OMS, conforme a lo dispuesto en el artculo 3.
Artculo 5 - Toda persona interesada puede presentar una objecin formal a una denominacin propuesta dentro de los
cuatro meses siguientes a su publicacin en Informacin Farmacutica OMS, conforme a lo dispuesto en el artculo 3.
Esa objecin deber acompaarse de los siguientes datos:
i) la identidad de la persona que formula la objecin;
ii) las causas que motivan su inters por la denominacin; y
iii) las causas que motivan su objecin a la denominacin propuesta.
Artculo 6 - Cuando se haya presentado una objecin formal en la forma prevista en el artculo 5, la OMS podr
reconsiderar el nombre propuesto o utilizar sus buenos oficios para intentar lograr que se retire la objecin. La OMS no
seleccionar como denominacin comn internacional una denominacin a la que se haya hecho una objecin formal,
presentada segn lo previsto en el artculo 5, que no haya sido retirada, todo ello sin perjuicio de que la Organizacin
examine otra denominacin o denominaciones sustitutivas.
Artculo 7 - Cuando no se haya formulado ninguna objecin en la forma prevista en el artculo 5, o cuando todas las
objeciones presentadas hayan sido retiradas, la Secretara notificar, conforme a lo dispuesto en el prrafo a) del artculo 3,
que la denominacin ha sido seleccionada por la OMS como denominacin comn internacional recomendada.
Artculo 8 - Al comunicar a los Estados Miembros una denominacin comn internacional, conforme a lo previsto en el
artculo 7, la Secretara:
a) solicitar que esta denominacin sea reconocida como denominacin comn para la sustancia de que se trate; y
b) solicitar a los Estados Miembros que adopten todas las medidas necesarias para impedir la adquisicin de derechos de
patente sobre la denominacin, y prohban que sea registrada como marca de fbrica o como nombre comercial.
Artculo 9
a) En el caso excepcional de que, debido a su semejanza con otra denominacin utilizada en las prcticas farmacuticas
y/o de prescripcin, una denominacin comn internacional recomendada anteriormente ocasione errores de medicacin,
prescripcin o distribucin, o suponga un riesgo manifiesto de que esto ocurra, y parezca que tales errores o potenciales
errores no sean fcilmente subsanables con otras medidas que no sean la posible sustitucin de esa denominacin comn
internacional recomendada anteriormente; en el caso de que una denominacin comn internacional recomendada
anteriormente difiera considerablemente de la denominacin comn aprobada en un nmero importante de Estados
Miembros, o en otras circunstancias excepcionales que justifiquen el cambio de una denominacin comn internacional
recomendada, cualquier persona interesada puede presentar propuestas en este sentido. Esas propuestas se presentarn
en los formularios que se proporcionen a estos efectos e incluirn los siguientes datos:
i) la identidad de la persona que presenta la propuesta;
ii) las causas que motivan su inters en la sustitucin propuesta;
iii) las causas que motivan la propuesta; y
iv) una descripcin, acompaada de pruebas documentales, de las otras medidas que se hayan adoptado con el
fin de resolver la situacin y de los motivos por los cuales dichas medidas no han sido suficientes.
Entre esas propuestas podr figurar una relativa a una nueva denominacin comn internacional sustitutiva,
formulada con arreglo a los Principios generales y que tenga en cuenta la sustancia farmacutica para la que se proponga
la nueva denominacin comn internacional sustitutiva.
462
La Secretara enviar al Grupo de Expertos en DCI y al solicitante inicial o a su sucesor (en el caso de que sea
una persona diferente de la que ha presentado la propuesta de sustitucin y siempre que el solicitante inicial o su sucesor
sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones
industriales) una copia de la propuesta, para que sea examinada de conformidad con el procedimiento descrito en el
prrafo b) infra.
Adems, la Secretara solicitar observaciones sobre la propuesta:
i) a los Estados Miembros y a las comisiones nacionales y regionales de las farmacopeas u otros organismos
designados por los Estados Miembros (ello se har incluyendo una notificacin a tal efecto en la carta a la que se
refiere el prrafo a) del artculo 3), y
ii) a cualquier persona que tenga un inters especial en la sustitucin propuesta.
Al solicitar que se formulen estas observaciones se facilitarn los siguientes datos:
i) la denominacin comn internacional recomendada que se propone sustituir (y la denominacin sustitutiva
propuesta, si se ha facilitado);
ii) la identidad de la persona que ha presentado la propuesta de sustitucin (si lo pide esa persona);
iii) la identidad de la sustancia a la que se refiere la sustitucin propuesta y las razones para presentar la
propuesta de sustitucin;
iv) el plazo fijado para recibir observaciones, as como el nombre y la direccin de la persona a quien deban
dirigirse; y
v) los poderes conferidos para el caso a la OMS y una referencia al presente procedimiento.
Toda persona puede formular a la OMS observaciones sobre la sustitucin propuesta dentro de los cuatro meses
siguientes a la fecha en que se realiz la solicitud de observaciones.
b) Una vez agotado el mencionado plazo para la formulacin de observaciones, la Secretara enviar todos los comentarios
recibidos al Grupo de Expertos en DCI, al solicitante inicial o a su sucesor, y a la persona que haya presentado la
propuesta de sustitucin. Si despus de examinar la propuesta de sustitucin y las observaciones recibidas, el Grupo de
Expertos en DCI, la persona que haya presentado la propuesta de sustitucin y el solicitante inicial, o su sucesor, estn de
acuerdo en la necesidad de sustituir la denominacin comn internacional recomendada anteriormente, la Secretara
remitir la propuesta de sustitucin al Grupo de Expertos en DCI para que la tramite.
No obstante lo anterior, el solicitante inicial o su sucesor no tendrn derecho a impedir el acuerdo sobre una propuesta de
sustitucin en el caso de que hayan dejado de tener un inters demostrable en la denominacin comn internacional cuya
sustitucin se propone.
En caso de que la propuesta de sustitucin sea presentada al Grupo de Expertos en DCI para que la tramite, este
grupo seleccionar una nueva denominacin comn internacional de conformidad con los Principios generales a los que se
refiere el artculo 2 y al procedimiento establecido en los artculos 3 a 8 inclusive. En ese caso, en las notificaciones que la
Secretara ha de enviar con arreglo a los artculos 3 y 7, respectivamente, incluida la notificacin al solicitante inicial o a su
sucesor (en el caso de que no sea la misma persona que propuso la sustitucin y siempre que el solicitante inicial o su
sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto con las asociaciones
industriales), se indicar que la nueva denominacin sustituye a una denominacin comn internacional recomendada
anteriormente y que los Estados Miembros podrn, si lo estiman oportuno, adoptar disposiciones transitorias aplicables a
los productos existentes en cuya etiqueta se utilice, con arreglo a la legislacin nacional, la denominacin comn
internacional recomendada anteriormente que se haya sustituido.
En caso de que, despus de haber estudiado la propuesta de sustitucin y los comentarios recibidos de conformidad
con el procedimiento descrito anteriormente, el Grupo de Expertos en DCI, el solicitante inicial o su sucesor y la persona
que haya presentado la propuesta de sustitucin no lleguen a un acuerdo sobre la existencia de razones poderosas para
sustituir una denominacin comn internacional recomendada anteriormente, esta denominacin se mantendr (siempre en
el entendimiento de que el solicitante inicial o su sucesor no tendrn derecho a impedir el acuerdo sobre una propuesta de
sustitucin en el caso de que hayan dejado de tener un inters demostrable en la denominacin comn internacional cuya
sustitucin se propone). En ese caso, la Secretara comunicar a la persona que haya propuesto la sustitucin, as como
al solicitante inicial o a su sucesor (en el caso de que no sea la misma persona que propuso la sustitucin y siempre que el
solicitante inicial o su sucesor sean conocidos o puedan ser encontrados mediante esfuerzos diligentes, como el contacto
con las asociaciones industriales), a los Estados Miembros, a las comisiones nacionales y regionales de las farmacopeas o
463
a otros organismos designados por los Estados Miembros y a cualquier otra persona que tenga inters en la sustitucin
propuesta, que, pese a la presentacin de una propuesta de sustitucin, se ha decidido mantener la denominacin comn
internacional recomendada anteriormente (con una descripcin de la o las razones por las que se ha considerado que la
propuesta de sustitucin no estaba respaldada por razones suficientemente poderosas).
ANEXO 2
PRINCIPIOS GENERALES DE ORIENTACIN PARA FORMAR DENOMINACIONES

COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACUTICAS1
1. Las denominaciones comunes internacionales (DCI) debern diferenciarse tanto fontica como ortogrficamente. No
debern ser incmodamente largas, ni dar lugar a confusin con denominaciones de uso comn.
2. La DCI de una sustancia que pertenezca a un grupo de sustancias farmacolgicamente emparentadas deber mostrar
apropiadamente este parentesco. Debern evitarse las denominaciones que puedan tener connotaciones anatmicas,
fisiolgicas, patolgicas o teraputicas para el paciente.
Estos principios primarios se pondrn en prctica utilizando los siguientes principios secundarios:
3. Al idear la DCI de la primera sustancia de un nuevo grupo farmacolgico, deber tenerse en cuenta la posibilidad de
poder formar DCI convenientes para las sustancias emparentadas que se agreguen al nuevo grupo.
4. Al idear DCI para cidos, se preferirn las de una sola palabra; sus sales debern denominarse sin modificar el nombre
del cido: p. ej. oxacilina y oxacilina sdica, ibufenaco y ibufenaco sdico.
5. Las DCI para las sustancias que se usan en forma de sal debern en general aplicarse a la base activa o al cido activo.
Las denominaciones para diferentes sales o esteres de la misma sustancia activa solamente debern diferir en el nombre
del cido o de la base inactivos.
En los compuestos de amonio cuaternario, el catin y el anin debern denominarse adecuadamente por separado, como
componentes independientes de una sustancia cuaternaria y no como sales de una amina.
6. Deber evitarse el empleo de letras o nmeros aislados; tambin es indeseable el empleo de guiones.
7. Para facilitar la traduccin y la pronunciacin, se emplearn de preferencia las letras f en lugar de ph, t en lugar
de th, e en lugar de ae u oe, e i en lugar de y; se deber evitar el empleo de las letras h y k.
8. Siempre que las denominaciones propuestas estn de acuerdo con estos principios, recibirn una consideracin
preferente las denominaciones propuestas por la persona que haya descubierto las sustancias, o que fabrique y
comercialice por primera vez una sustancia farmacutica, as como las denominaciones ya adoptadas oficialmente en
cualquier pas.
9. El parentesco entre sustancias del mismo grupo se pondr de manifiesto en las DCI (vase el Principio 2) utilizando una
partcula comn. En la lista que figura a continuacin se indican ejemplos de partculas para grupos de sustancias, en
2
particular para grupos nuevos. Existen muchas otras partculas que se usan habitualmente. Cuando una partcula aparece
sin guin alguno, puede utilizarse en cualquier lugar de la palabra.
1
En su 20 informe (OMS, Serie de Informes Tcnicos, N 581, 1975), el Comit de Expertos de la OMS en Denominaciones Comunes para las Sustancias
Farmacuticas revis los Principios generales para formar denominaciones comunes internacionales (DCI), y su procedimiento de seleccin, a la luz de las
novedades registradas en los ltimos aos en materia de compuestos farmacuticos. El cambio ms importante haba consistido en hacer extensivo a la
denominacin de sustancias qumicas sintticas el mtodo utilizado hasta entonces para las sustancias originadas en productos naturales o derivadas de stos.
Dicho mtodo conlleva la utilizacin de una partcula caracterstica que indica una propiedad comn a los miembros de un grupo. En el citado informe se
examinan en detalle las razones y consecuencias de este cambio.
Los Principios generales de orientacin se actualizaron durante la 13 consulta sobre denominaciones comunes para sustancias farmacuticas (Ginebra, 27 a 29 de
abril de 1983) (PHARM S/NOM 928, 13 de mayo de 1983, revisado el 18 de agosto de 1983).
2
En el documento de trabajo WHO/EMP/QSM/2009.3, que se actualiza peridicamente y puede solicitarse al Programa sobre Denominaciones Comunes
Internacionales, OMS, Ginebra, figura una lista ms amplia de partculas.
464
Latin
-acum
-adolum
-adol-astum
-astinum
-azepamum
bol
-cain-cainum
cef-cillinum
-conazolum
cort
-coxibum
-entanum
gab
gado-gartranum
gest
gli
io-metacinum
-mycinum
-nidazolum
-ololum
-oxacinum
-platinum
-poetinum
-pril(at)um
-profenum
prost
-relinum
-sartanum
-vaptanum
vin-vin-
Espaol
-aco
-adol )
-adol- )
-ast
-astina
-azepam
bol
-cana-canacef- cilina
-conazol
cort
-coxib
-entn
gab
gado-gatrn
gest
gli
io-metacina
-micina
-nidazol
-olol
-oxacino
-platino
-poetina
-pril(at)
-profeno
prost
-relina
-sartn
-vaptn
vin)
-vin)
antiinflamatorios derivados del ibufenaco

analgsicos
antiasmticos, sustancias antialrgicas cuya accin principal no es la antihistamnica
antihistamnicos
derivados del diazepam
esteroides anabolizantes
antiarrtmicos de clase I, derivados de procainamida y lidocana
anestsicos locales
antibiticos, derivados del cido cefalospornico
antibiticos derivados del cido 6-aminopenicilnico
antifngicos sistmicos derivados del miconazol
corticosteroides, excepto derivados de prednisolona
inhibidores selectivos de ciclooxigenasa
antagonistas del receptor de endotelina
gabamimticos
agentes para diagnstico derivados de gadolinio
inhibidores de la trombina antitrombticos
esteroides progestgenos
hipoglucemiantes, antihiperglucmicos
medios de contraste iodados
antiinflamatorios derivados de indometacina
antibiticos producidos por cepas de Streptomyces
antiprotozoarios y radiosensibilizadores derivados de metronidazol
antagonistas de receptores -adrenrgicos
antibacterianos derivados del cido nalidxico
antineoplsicos derivados del platino
factores sanguneos similares a la eritropoyetina
inhibidores de la enzima conversora de la angiotensina
antiinflamatorios derivados del ibuprofeno
prostaglandinas
pptidos estimulantes de la liberacin de hormonas hipofisarias
antihipertensivos (no peptdicos) antagonistas del receptorde angiotensina II
antagonistas del receptor de vasopresina
alcaloides de la vinca
465

ВОЗ Международные Названия Субстанций

Încărcat de

Informații document

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

ВОЗ Международные Названия Субстанций

Încărcat de

Drepturi de autor:

Formate disponibile

WHO Drug Information, Vol. 25, No.

Proposed INN: List 106

International Nonproprietary Names for

Dnominations communes internationales des

Denominaciones Comunes Internacionales para

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed International Nonproprietary Names: List 106

Dnominations communes internationales proposes: Liste 106

Denominaciones Comunes Internacionales Propuestas: Lista 106

Chemical name or description: Action and use: Molecular formula

Nom chimique ou description: Proprits et indications: Formule brute

Nombre qumico o descripcin: Accin y uso: Frmula molecular

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

(4S)-4-(3-[ F]fluoropropyl)-L-glutamic acid

acide (4S)-4-(3-[ F]fluoropropyl)-L-glutamique

cido (4S)-4-(3-[ F]fluoropropil)-L-glutmico

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

siRNA inhibitor of 2-adrenergic receptor production;

petit ARN interfrant (siRNA) inhibiteur de la production du rcepteur

ARN interferente pequeo (siRNA) inhibidor de la produccin del

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

immunoglobulin VH-linker-VH fragment, anti-[Homo sapiens VWF

immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF

inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protine 1

inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

heterodimer of human glycoprotein hormones alpha chain and

htrodimre constitu de la chane alpha des hormones

heterodmero formado por la cadena alfa de las hormonas

Alpha subunit / Sous-unit alpha / Subunidad alfa

Beta subunit / Sous-unit bta / Subunidad beta

R = -Fuc or H, R3 = -Sia or H, R4 and R6 = R33--Gal4--Gl-N or H

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

iduronate 2-sulfatase (-L-iduronate sulfate sulfatase), proenzyme

iduronato 2-sulfatasa (-L-iduronato sulfato sulfatasa), proenzima

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilacin (N)

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

immunoglobulin G4-kappa, anti-[Homo sapiens SELP (selectin P,

immunoglobuline G4-kappa, anti-[Homo sapiens SELP (slectine P,

inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina

Light chain / Chane lgre / Cadena ligera

WHO Drug Information, Vol. 25, No. 4, 2011

Proposed INN: List 106

Proposed INN: List 106

WHO Drug Information, Vol. 25, No. 4, 2011

cross-linked polymer of calcium 2-fluoroprop-2-enoate with

polymre rticul de 2-fluoroprop-2-noate de calcium avec du

polmero reticulado de 2-fluoroprop-2-enoato de calcio con